Online Supplement

Management of Atrial Fibrillation: Complete Guidelines Listing

Laurent Macle, MD (Co-Chair), Jason Andrade, MD, Clare Atzema, MD, Alan D. Bell, MD, John A. Cairns, MD, Stuart Connolly, MD, Jafna L. Cox, MD, Paul Dorian, MD, David J. Gladstone, MD, Jeff S. Healey, MD, Kori Leblanc, PharmD, L. Brent Mitchell, MD, Stanley Nattel, MD, Ratika Parkash, MD, Louise Pilote, MD, Mike Sharma, MD, Allan Skanes, MD, Mario Talajic, MD, Teresa S.M Tsang, MD, Subodh Verma, MD, and Atul Verma, MD (Co-Chair), on behalf of the CCS Atrial Fibrillation Guidelines Committee*

* For a complete listing of the primary and secondary members of the CCS Atrial Fibrillation Guidelines Committee along with their affiliations, see the end of this document.

This summary lists all recommendations presently in force. The recommendations indicated are the most recently established in each category, with the year in which the recommendation was established being indicated.
# Table of Contents

List of Abbreviations .................................................................................................................. 9

## Part 1 - Initial Evaluation of Atrial Fibrillation ..................................................................... 12

Recommendation 1 – Complete history and physical examination (2010) ............................... 12
Recommendation 3 – Quality of life – CCS-AF scale (2010) .................................................... 12
Recommendation 4 - Underlying causes or precipitating factors (2010) .............................. 12

Table S1 (Table 1 from 2010) Etiology and Initial Investigations: Baseline Evaluation of Atrial
Fibrillation for All Patients ........................................................................................................... 13
Table S2 (Table 3 from 2010) Etiology and Initial Investigations: Additional Investigations Useful
in Selected Cases........................................................................................................................ 14
Table S3 (Table 4 from 2010) Etiology and Initial Investigations: Potential Causes of Atrial
Fibrillation ........................................................................................................................................ 15

## Part 2 – Detection of Atrial Fibrillation in Patients with Stroke ......................................... 16

Recommendation 1 – At least 24 hours of ECG monitoring (2014) ........................................... 16
Recommendation 2 – For selected older patients, additional ambulatory monitoring (2014) ...... 16

## Part 3 – Rate Management of AF ....................................................................................... 17

Recommendation 1 – Goals of rate control therapy (2010) ....................................................... 17
Recommendation 2 – Ventricular rate assessment (2010) .......................................................... 17
Recommendation 3 – Heart rate during exercise and exertional symptoms (2010) .................... 17
Recommendation 4 – Aim for a resting heart rate of <100 bpm (2010) ..................................... 17
Recommendation 5 – Beta-blockers or nondihydropyridine CCBs as initial therapy (2010) .... 17
Recommendation 6 – Digoxin rate control: selected sedentary and LV systolic dysfunction patients (2010) ................................................................. 17
Recommendation 7 – Digoxin added when other therapies fail (2016, updated from 2010) ..... 17
Recommendation 8 – Amiodarone for rate control therapy in exceptional cases (2010) .......... 18
Recommendation 9 – Dronedarone, not for patients with permanent AF (2012) ....................... 18
Recommendation 10 – Dronedarone, not for patients with history of HF (2012) ....................... 18
Recommendation 11 – Dronedarone, to be used with caution with patients taking digoxin (2012) 18
Recommendation 12 – Beta-blockers as initial therapy in patients with MI or LV systolic dysfunction (2010) ....................................................................................................................... 18
Recommendation 13 – AVN ablation/pacemaker in symptomatic drug-refractory patients (2010) . 19
Figure S1 (Figure 3 from 2012 Update): Summary of recommendations for choice of rate-control agents for various conditions

Part 4 – Rhythm Management of AF

Recommendation 1 – Treatment of precipitating or reversible conditions (2010)

Recommendation 2 – Rhythm control strategy for patients symptomatic on rate control therapy (2010)

Figure S2 (Figure 3 from 2014 Update): Approach to rate and/or rhythm control of AF in patients presenting with symptomatic AF.

Recommendation 3 – Goal of rhythm control therapy (2010)

Recommendation 4 – Maintenance antiarrhythmic drugs first-line in patients with recurrent AF (2010)

Figure S3 (Figure 4 from 2012 Update): Summary of recommendations for choice of rhythm control therapy in patients with normal systolic left ventricular function and no history of congestive heart failure.

Figure S4 (Figure 5 from 2012 Update): Summary of recommendations for choice of rhythm control therapy in patients with a history of congestive heart failure (current or remote) or left ventricular systolic dysfunction.

Recommendation 5 – Avoid antiarrhythmic in patients with advanced sinus or AV node disease (2010)

Recommendation 6 – AV blocking agent to be used along with a class I antiarrhythmic drug (2010)


Recommendation 8 – Electrical or pharmacological cardioversion for sinus rhythm restoration (2010)

Recommendation 9 – Pre-treatment with antiarrhythmic drugs before electrical cardioversion (2010)

Recommendation 10 – For symptomatic bradycardia, dual-chamber pacing (2010)

Recommendation 11 – Pacemaker to be programmed to minimize ventricular pacing (2010)

Part 5 – Catheter Ablation of Atrial Fibrillation and Atrial Flutter

Recommendation 1 – Catheter ablation in symptomatic drug-refractory patients (2014)

Recommendation 2 – Catheter ablation as first-line therapy in highly selected patients (2014)

Table S4 (Table 2 from 2014 Update): Balance of benefit to risk for catheter ablation in patients with symptomatic atrial fibrillation

Recommendation 3 – Catheter ablation only by operators with expertise and high volumes (2014)
Recommendation 4 – Curative catheter ablation as first-line therapy for typical atrial flutter (2010) ........................................24
Recommendation 5 – Catheter ablation of accessory pathway (2010) .................................................................25
Recommendation 6 - Exclude reentrant tachycardia in young patients with lone paroxysmal AF (2010) .................................................................25

Part 6 – Prevention of Stroke and Systemic Embolism in Atrial Fibrillation/Flutter ........................26

Recommendation 1 – Stratification of patients using a predictive index for stroke risk (2014) .......26

Figure S5 (Figure 1 from 2016 Update): The simplified “CCS Algorithm” for decisions on which patients with atrial fibrillation (AF) or atrial flutter should receive oral anticoagulation (OAC) therapy. ..........................................................................................................................26

Table S5 (Table 1 from 2014 AF Guidelines Companion): Definitions of Stroke Risk Factors ........27

Recommendation 2 – OAC therapy for patients ≥ 65 years or CHADS2 ≥ 1 (2014) ...............................27

Recommendation 3 – ASA for patients with no risks besides arterial vascular disease (2014) .........27

Recommendation 4 – No antithrombotic therapy for patients with no major risks (2014) ............27

Recommendation 5 – Most patients should receive NOAC (2014) .........................................................27

Recommendation 6 – Warfarin when mechanical valve, mitral stenosis or renal dysfunction (2014) ........................................................................................................28

Table S6 (Table 5 from 2014 AF Guidelines Companion): Expert opinion survey regarding the clinical use of a NOAC in relation to the following commonly encountered scenarios: Would you consider NOAC use to be: (1) contraindicated or (2) not contraindicated (ie, reasonable to use) with the following valvular disorders? ........................................................................................................28

Recommendation 7 – Patients who refuse OAC should receive ASA plus clopidogrel (2014) .........29

Recommendation 8– OAC therapy for highly selected patients with subclinical AF (2014) ............29

Recommendation 9 –OAC for 3 weeks before and at least 4 weeks post cardioversion (2010) ......29

Recommendation 10 – Annual renal function assessment (2012) .........................................................30

Recommendation 11 – Antithrombotic therapy should relate to CrCl (2012) ............................................30

Table S7 (Table 6 from 2014 AF Guidelines Companion): Recommendations for dosage of oral anticoagulants based on renal function .................................................................................................31

Recommendation 12 – LAA closure devices to be used only in research and, exceptional cases (2014) ..................................................................................................................31

Recommendation 13 – Acute management of stroke patients as per AHA/ASA guidelines (2010)...31

Recommendation 14 – Hemorrhage on OAC to be managed per AACP guidelines (2010) .............31

Recommendation 15 – Idarucizimab for emergency reversal of dabigatran’s anticoagulant effect (2016) ........................................................................................................................................31
Part 7 – Management of Antithrombotic Therapy in patients with concomitant AF and CAD

General recommendations regarding antithrombotic therapy in the context of concomitant AF and CAD (asymptomatic, stable CAD, elective PCI, NSTEMI or STEMI):

Recommendation 1 – Antithrombotic therapy based on a balanced assessment of a patient’s risk of stroke (2016)

Recommendation 2 – Most patients with an indication for OAC in the presence of CAD should receive a NOAC (2016)

For patients with AF, with an indication for primary CAD prevention or stable CAD/arterial vascular disease (peripheral vascular disease or aortic plaque), the selection of antithrombotic therapy should be based on their risk of stroke as follows (Figure 2, from 2016 update):

Recommendation 3 – No antithrombotic therapy for patients with no evidence of manifest CAD/vascular disease (2016)

Recommendation 4 – ASA for patients with no risks besides CAD/arterial vascular disease (2016)

Recommendation 5 – OAC therapy for patients ≥ 65 years or CHADS2 ≥ 1 (2016)

For patients with AF and recent elective PCI, the selection of antithrombotic therapy should be based on their risk of stroke as follows (Figure 3, from 2016 update):

Recommendation 6 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 7 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 8 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 9 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 10 (2016)

For patients with AF, in association with Non-ST Elevation Acute Coronary Syndrome (NSTEMI) or ST Segment Elevation Myocardial Infarction (STEMI), the selection of antithrombotic therapy should be based on their risk of stroke as follows (Figure 4, from 2016 update):

Recommendation 11 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 12 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 13 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 14 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 15 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 16 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 17 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 18 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 19 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)

Recommendation 20 (2016)
Part 8 – Management of Recent Onset Atrial Fibrillation and Flutter in the Emergency Department...41

Recommendation 1 – Rate or rhythm control therapy for patients with recent onset AF/AFL (2010) ........................................................................................................... 41
Recommendation 2 – Hemodynamically stable patients with AF/AFL <48 hours (2010) .................. 41
Recommendation 3 – Electrical cardioversion with 150-200 joules biphasic waveform (2010).... 41
Recommendation 4 – WPW/rapid response, DC cardioversion for hemodynamically unstable (2010) ........................................................................................................... 41
Recommendation 5 – Lower stroke risk and AF < 48 hours, may undergo cardioversion (2014)..... 42
Recommendation 6 – High stroke risk: rate control and OAC therapy 3 weeks precardioversion (2014) ........................................................................................................... 42
Recommendation 7 – High stroke risk and cardioversion after TEE (2014) ................................. 42
Recommendation 8 – Hemodynamic instability: consider immediate DC cardioversion (2014)..... 43
Recommendation 9 – Hospital admission for decompensated HF or myocardial ischemia (2010) ... 43
Recommendation 10 - Admission for highly symptomatic patients with unachievable rate control (2010) ........................................................................................................... 43
Recommendation 11 – Antiarrhythmic drug therapy post-cardioversion (2010) .......................... 43

Figure S9 (Figure 2 from 2014 Update): Decision algorithm for management of oral anticoagulation (OAC) therapy for patients who present to the emergency department (ED) with recent-onset atrial fibrillation (AF) requiring rate control or cardioversion (CV) in the ED. ........... 44

Table S8 (Table 2 from 2010): Recommended intravenous drugs for heart rate control in the ED ........................................................................................................... 44

Table S9 (Table 3 from 2010): Recommended Drugs for Pharmacological Conversion in the ED 44
Recommendation 1 – Surgical AF ablation in association with cardiac surgery (2016, updated from 2010) .................................................................45

Recommendation 2 – Asymptomatic lone AF, not to be considered for surgical therapy (2010) ..... 45

Recommendation 3 – Closure of the left atrial appendage as part of surgical ablation of AF associated with cardiac surgery (2016, updated from 2010) .................................................................45

Recommendation 4 – Continue OAC following surgical AF ablation per risk factors (2010) ........45

Recommendation 5 – Continue OAC following surgical AF ablation for all MVRs (2010) ..........46

Part 10 – Prevention and Treatment of Atrial Fibrillation following Cardiac Surgery ......................47

Recommendation 1 – Beta-blockers to be continued through the operative procedure (2010) ......47

Recommendation 2 – Amiodarone for patients with contraindications to beta-blockers (2010) .....47

Recommendation 3 – Consider IV magnesium, colchicine, biatrial pacing when beta-blocker and amiodarone contraindicated (2016, updated from 2010) ........................................................................47

Recommendation 4 – High risk and sotalol or combination prophylaxis (2010) .........................47

Recommendation 5 – Consideration of OAC for postoperative AF >72 hours (2010) ..............48

Recommendation 6 – Temporary epicardial pacing electrode wires at surgery (2010) ............48

Recommendation 7 – Post-op AF with rapid response: beta-blocker, CCB, or amiodarone (2010) ..48

Recommendation 8 - Rate-control or rhythm-control strategy for post-op AF (2016, updated from 2010) .................................................................................................48

Recommendation 9 – Reconsideration of ongoing therapy 6-12 weeks post-op (2010) ..........49

Part 11 – Peri-procedural Anticoagulation Management ..............................................................50

Recommendation 1 - Decision considerations (2014) ................................................................50

Recommendation 2 – OAC interruption not necessary for most lower risk procedures (2016, updated from 2014) .......................................................................................50

Recommendation 3 – OAC interruption of anticoagulant therapy for medium to high risk procedures (2014) ....................................................................................................50

Table S10 (Table 1 from 2016): Bleeding risks for various invasive/surgical procedures ............50

Recommendation 4 - Aspirin or clopidogrel interruption 5-7 days prior to procedure (2016, updated from 2014) .......................................................................................................51

Recommendation 5 - Warfarin interruption 5 days prior to procedure (2014) .........................51

Recommendation 6 – Stop apixaban or rivaroxaban 1-2 days pre-low risk; 2-3 days pre-medium or high-risk procedure (2014) .................................................................51

Recommendation 7 – Stop dabigatran 1-2 days prior pre-low risk; 2-3 days pre-medium or high-risk procedure, depending on renal function (2014) ...........................52
Recommendation 8 - Bridging therapy in a patient at high risk of thromboembolic events (2016, updated from 2014) ........................................................................................................................................ 52

Recommendation 9 – No bridging for patients on NOAC for procedures requiring interruption of anticoagulation (2016) ........................................................................................................................................ 52

Recommendation 10 - Heparin bridging pre-procedure (2016, updated from 2014) ........................................... 52

Recommendation 11 – Heparin bridging post-procedure (2016, updated from 2014) ................................. 52

Recommendation 12 – Warfarin, ASA, clopidogrel restarted when hemostasis is established (2014) ........................................................................................................................................ 52

Recommendation 13 – NOAC restarted one day after hemostasis is established (2014) ......................... 53

Canadian Cardiovascular Society Atrial Fibrillation Primary Panel .................................................................................................................. 54

Canadian Cardiovascular Society Atrial Fibrillation Secondary Panel .............................................................................................................. 55
List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACS</td>
<td>Acute Coronary Syndrome</td>
</tr>
<tr>
<td>ACTIVE-A</td>
<td>Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events Trial</td>
</tr>
<tr>
<td>ADP</td>
<td>Adenosine Diphosphate</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial Fibrillation</td>
</tr>
<tr>
<td>AFL</td>
<td>Atrial Flutter</td>
</tr>
<tr>
<td>ANDROMEDA</td>
<td>Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease</td>
</tr>
<tr>
<td>APTT</td>
<td>Activated Partial Thromboplastin Time</td>
</tr>
<tr>
<td>ASA</td>
<td>Acetylsalicylic Acid</td>
</tr>
<tr>
<td>ATHENA</td>
<td>A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter</td>
</tr>
<tr>
<td>AV</td>
<td>Atrioventricular</td>
</tr>
<tr>
<td>AVNRT</td>
<td>Atrioventricular Node Re-entry Tachycardia</td>
</tr>
<tr>
<td>AVRT</td>
<td>Atrioventricular Re-entry Tachycardia</td>
</tr>
<tr>
<td>BMS</td>
<td>Bare Metal Stent</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary Artery Bypass Graft</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary Artery Disease</td>
</tr>
<tr>
<td>CCB</td>
<td>Calcium Channel Blockers</td>
</tr>
<tr>
<td>CCS</td>
<td>Canadian Cardiovascular Society</td>
</tr>
<tr>
<td>CHADS₂</td>
<td>The CHADS₂ score is a measure of the risk of stroke in patients with atrial fibrillation, with scores ranging from 0 to 6 and higher scores indicating a greater risk. Congestive heart failure, hypertension, an age of 75 years or older, and diabetes mellitus are each assigned 1 point, and previous stroke or transient ischemic attack is assigned 2 points; the score is calculated by summing all the points for a given patient.</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>CKD</td>
<td>Chronic Kidney Disease</td>
</tr>
</tbody>
</table>
**COPD**: Chronic Obstructive Pulmonary Disease

**CrCl**: Creatinine Clearance

**CV**: Cardioversion

**DAPT**: Dual-Antiplatelet Therapy

**DES**: Drug-Eluting Stent

**DM**: Diabetes Mellitus

**ECG**: Electrocardiogram

**ED**: Emergency Department

**EF**: Ejection Fraction

**HAS-BLED**: Acronym of the major factors associated with bleeding risk in patients with atrial fibrillation receiving oral anticoagulation: Hypertension [uncontrolled, >160 mmHg systolic], Abnormal renal/liver function, Stroke, Bleeding history or predisposition [anemia], Labile INR [i.e. therapeutic time in range <60%], Elderly (>65) and Drugs/alcohol concomitantly [antiplatelet agents, non-steroidal anti-inflammatory drugs]

**HF**: Heart Failure

**Hx**: History

**ICH**: Intracerebral Hemorrhage

**INR**: International Normalized Ratio

**LA**: Left Atrium

**LAA**: Left Atrial Appendage

**LMWH**: Low Molecular Weight Heparin

**LV**: Left Ventricle

**MI**: Myocardial Infarction

**MVR**: Mitral Valve Replacement

**NOAC**: Non-Vitamin K Antagonist Oral Anticoagulant

**NSTEACS**: Non ST-Elevation Acute Coronary Syndrome

**OAC**: Oral Anticoagulant
PAD: Peripheral Artery Disease

PALLAS: Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy Trial

PCI: Percutaneous Coronary Intervention

POAF: Postoperative Atrial Fibrillation

QOL: Quality of Life

RCT: Randomized Controlled Trial

RE-VERSE AD: Reversal Effects of Idarucizumab on Active Dabigatran

SAF: Severity of Atrial Fibrillation

SCAF: Subclinical Atrial Fibrillation

SSE: Stroke and systemic Embolism

STEMI: ST-Elevation Myocardial Infarction

TEE: Trans-Esophageal Echocardiography

TIA: Transient Ischemic Attack

TT: Thrombin Time

TT: Triple Therapy

UFH: Unfractionated Heparin

VF: Ventricular Fibrillation

WOEST: What is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting Trial
Part 1 - Initial Evaluation of Atrial Fibrillation

Recommendation 1 - Complete history and physical examination (2010)
All patients with atrial fibrillation should undergo a complete history and physical examination, electrocardiogram, echocardiogram, and basic laboratory investigations. Details are highlighted in Table 1 (Strong Recommendation; Low Quality Evidence). Other ancillary tests should be considered under specific circumstances. Details included in Table 2 (Strong Recommendation; Low Quality Evidence).

Values and preferences (2010)
This recommendation places a high value on a comprehensive evaluation of patients with AF and a lower value on initial costs to the health care system.

Recommendation 2 - Well-being, symptoms, and quality of life (2010)
We recommend that the assessment of patient well-being, symptoms, and quality of life be part of the evaluation of every patient with AF (Strong Recommendation, Low Quality Evidence).

Recommendation 3 - Quality of life – CCS-AF scale (2010)
We suggest that the quality of life of the AF patient be assessed in routine care using the CCS SAF scale (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2010)
Recommendations 2 and 3 recognize that improvement in quality of life is a high priority for therapeutic decision making.

Recommendation 4 - Underlying causes or precipitating factors (2010)
Underlying causes or precipitating factors for AF including hypertension should be identified and treated. Details are highlighted in Table 3 (Strong Recommendation; High Quality of Evidence).

Values and preferences (2010)
This recommendation recognizes that therapy of underlying etiology can improve management of AF and that failure to recognize underlying factors may result in deleterious effects.
**Table S1 (Table 1 from 2010) Etiology and Initial Investigations: Baseline Evaluation of Atrial Fibrillation for All Patients**

<table>
<thead>
<tr>
<th>History and Physical Exam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Establish Pattern (New Onset, Paroxysmal, Persistent or Permanent)</td>
</tr>
<tr>
<td>Establish Severity (including impact on quality of life)</td>
</tr>
<tr>
<td>Identify Etiology</td>
</tr>
<tr>
<td>Identify reversible causes (hyperthyroidism, ventricular pacing, supraventricular tachycardia, exercise, etc)</td>
</tr>
<tr>
<td>Identify risk factors whose treatment could reduce recurrent AF or improve overall prognosis (i.e. hypertension, sleep apnea, left ventricular dysfunction, etc)</td>
</tr>
<tr>
<td>Take social history to identify potential triggers (i.e. alcohol, intensive aerobic training, etc)</td>
</tr>
<tr>
<td>Elicit family history, to identify potentially heritable causes of AF (particularly in lone AF)</td>
</tr>
<tr>
<td>Determine thromboembolic risk</td>
</tr>
<tr>
<td>Determine bleeding risk to guide appropriate antiplatelet or antithrombotic therapy</td>
</tr>
<tr>
<td>Review prior pharmacologic therapy for AF, both for efficacy and adverse effects</td>
</tr>
<tr>
<td>Measure blood pressure and heart rate</td>
</tr>
<tr>
<td>Determine patient height and weight</td>
</tr>
<tr>
<td>Comprehensive precordial cardiac examination and assessment of jugular venous pressure, carotid and peripheral pulses to detect evidence of structural heart disease</td>
</tr>
</tbody>
</table>

**12-Lead Electrocardiogram**

<table>
<thead>
<tr>
<th>Document presence of AF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess for structural heart disease (myocardial infarction, ventricular hypertrophy, atrial enlargement, congenital heart disease) or electrical heart disease (Ventricular pre-excitation, Brugada syndrome)</td>
</tr>
<tr>
<td>Identify risk factors for complications of therapy for AF (conduction disturbance, sinus node dysfunction or repolarization). Document baseline PR, QT or QRS intervals.</td>
</tr>
</tbody>
</table>

**Echocardiogram**

<table>
<thead>
<tr>
<th>Document ventricular size, wall thickness and function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluate left atrial size (if possible, left atrial volume)</td>
</tr>
<tr>
<td>Exclude significant valvular or congenital heart disease (particularly atrial septal defects)</td>
</tr>
<tr>
<td>Estimate ventricular filling pressures and pulmonary arterial pressure</td>
</tr>
</tbody>
</table>

**Complete blood count, coagulation profile, renal function, thyroid and liver function**

**Fasting lipid profile, fasting glucose**
### Table S2 (Table 3 from 2010) Etiology and Initial Investigations: Additional Investigations Useful in Selected Cases

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Potential Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest radiography</td>
<td>Exclude concomitant lung disease, heart failure, baseline in patients receiving amiodarone</td>
</tr>
<tr>
<td>Ambulatory electrocardiography (holter monitor, event monitor, loop monitor)</td>
<td>Document AF, exclude alternative diagnosis (atrial tachycardia, atrial flutter. AVNRT/AVRT, ventricular tachycardia), symptom-rhythm correlation, assess ventricular rate control</td>
</tr>
<tr>
<td>Treadmill exercise test</td>
<td>Investigation of patients with symptoms of coronary artery disease, assessment of rate control</td>
</tr>
<tr>
<td>Trans-esophageal echocardiography</td>
<td>Rule out left atrial appendage thrombus, facilitate cardioversion in patients not receiving oral anticoagulation, more precise characterization of structural heart disease (mitral valve disease, atrial septal defects, cor triatriatum, etc)</td>
</tr>
<tr>
<td>Electrophysiologic Study</td>
<td>Patients with documented regular supraventricular tachycardia (i.e. atrial tachycardia, AVNRT/AVRT, atrial flutter) that is amenable to catheter ablation</td>
</tr>
<tr>
<td>Serum calcium and magnesium</td>
<td>In cases of suspected deficiency (i.e. diuretic use, gastrointestinal losses) which could influence therapy (i.e. sotalol)</td>
</tr>
<tr>
<td>Sleep Study (ambulatory oximetry or polysomnography)</td>
<td>In patients with symptoms of obstructive sleep apnea or in select patients with advanced symptomatic heart failure</td>
</tr>
<tr>
<td>Ambulatory blood pressure monitoring</td>
<td>In cases of borderline hypertension</td>
</tr>
<tr>
<td>Genetic testing</td>
<td>In rare cases of apparent familial AF (particularly with onset at a young age) with additional features of conduction disease, Brugada syndrome or cardiomyopathy</td>
</tr>
</tbody>
</table>
Table S3 (Table 4 from 2010) Etiology and Initial Investigations: Potential Causes of Atrial Fibrillation

<table>
<thead>
<tr>
<th>Cardiac Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Heart failure*</td>
</tr>
<tr>
<td>Coronary artery disease with prior myocardial infarction</td>
</tr>
<tr>
<td>Left ventricular dysfunction (systolic and diastolic)*</td>
</tr>
<tr>
<td>Including hypertrophic dilated and restrictive cardiomyopathies</td>
</tr>
<tr>
<td>Valvular heart disease</td>
</tr>
<tr>
<td>Congenital heart disease* (early repair of atrial septal defect)</td>
</tr>
<tr>
<td>Pericardial disease</td>
</tr>
<tr>
<td>Post-surgical (particularly cardiac surgery)</td>
</tr>
<tr>
<td>Sick sinus syndrome</td>
</tr>
<tr>
<td>Atrial fibrillation as a result of ventricular pacing*</td>
</tr>
<tr>
<td>Supraventricular tachycardia (including Wolf-Parkinson White syndrome, atrial tachycardia, atrial flutter or other)*</td>
</tr>
<tr>
<td>Genetic/familial</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-Cardiac Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive sleep apnea*</td>
</tr>
<tr>
<td>Obesity*</td>
</tr>
<tr>
<td>Excessive alcohol ingestion (acute or chronic)*</td>
</tr>
<tr>
<td>Hyperthyrodism*</td>
</tr>
<tr>
<td>Vagally-mediated (i.e. habitual aerobic training)*</td>
</tr>
<tr>
<td>Pulmonary disease (pneumonia, COPD, pulmonary embolism, pulmonary hypertension)</td>
</tr>
</tbody>
</table>

| Lone (idiopathic) Atrial Fibrillation                                           |
Part 2 – Detection of Atrial Fibrillation in Patients with Stroke

**Recommendation 1 – At least 24 hours of ECG monitoring (2014)**
For patients being investigated for an acute embolic ischemic stroke or TIA, we recommend at least 24 hours of ECG monitoring to identify paroxysmal AF potential candidates for OAC therapy (Strong recommendation, Moderate Quality Evidence).

**Values and preferences (2014)**
This recommendation places relatively high value on the facts that brain embolism can be the first manifestation of previously undiagnosed AF and stroke/TIA patients generally do not receive OAC unless AF is detected. This recommendation places relatively less weight on the absence of clinical trials evaluating OAC therapy among patients who have only very brief subclinical AF.

**Recommendation 2 – For selected older patients, additional ambulatory monitoring (2014)**
For selected older patients with an acute, non-lacunar, embolic stroke of undetermined source for which AF is suspected but unproven, we suggest additional ambulatory monitoring (beyond 24 hrs) for AF detection, where available, if it is likely that OAC therapy would be prescribed if prolonged* AF is detected (Conditional Recommendation, Moderate Quality Evidence) [*There are currently insufficient data to indicate what the minimum AF duration should be for OAC to be instituted, and expert opinion varies widely].

**Values and preferences (2014)**
This recommendation places high value on aggressively investigating selected patients with unexplained embolic stroke. The main rationale is to improve the identification of patients who would have an evidence-based change in management aimed at preventing recurrent strokes (i.e., switching from antiplatelet therapy to OAC therapy) if a clear diagnosis of AF is found. In cases where only very brief subclinical AF is detected, the role of OAC therapy is currently uncertain and treatment decisions should be individualized.
Part 3 – Rate Management of AF

**Recommendation 1 – Goals of rate control therapy (2010)**
We recommend that the goals of ventricular rate control should be to improve symptoms and clinical outcomes which are attributable to excessive ventricular rates (Strong Recommendation, Low Quality Evidence).

**Recommendation 2 – Ventricular rate assessment (2010)**
We recommend that ventricular rate be assessed at rest in all patients with persistent and permanent AF or AFL (Strong Recommendation, Moderate Quality Evidence).

**Recommendation 3 – Heart rate during exercise and exertional symptoms (2010)**
We recommend that heart rate during exercise be assessed in patients with persistent or permanent AF or AFL and associated exertional symptoms (Strong Recommendation, Moderate Quality Evidence).

**Recommendation 4 – Aim for a resting heart rate of <100 bpm (2010)**
We recommend that treatment for rate control of persistent or permanent AF or AFL should aim for a resting heart rate of <100 bpm (Strong Recommendation, High Quality Evidence).

**Values and preferences (2010)**
Recommendations 3, 4 and 5 place a high value on the randomized clinical trials and other clinical studies demonstrating that ventricular rate control of AF is an effective treatment approach for many patients with AF.

**Recommendation 5 – Beta-blockers or nondihydropyridine CCBs as initial therapy (2010)**
We recommend beta-blockers or nondihydropyridine calcium channel blockers as initial therapy for rate control of AF or AFL in most patients without a past history of myocardial infarction or left ventricular dysfunction (Strong Recommendation, Moderate Quality Evidence).

**Recommendation 6 – Digoxin rate control: selected sedentary and LV systolic dysfunction patients (2010)**
We suggest that digoxin not be used as initial therapy for active patients and be reserved for rate control in patients who are sedentary or who have left ventricular systolic dysfunction (Conditional Recommendation, Moderate Quality Evidence).

**Recommendation 7 – Digoxin added when other therapies fail (2016, updated from 2010)**
We suggest that digoxin can be considered as a therapeutic option to achieve rate-control in patients with AF and symptoms caused by rapid ventricular rates whose response to beta-blockers and/or calcium channel blockers is inadequate, or where such rate-controlling drugs are contraindicated or not tolerated (Conditional Recommendation, Moderate Quality Evidence).

**Values and preferences (2016)**
Digoxin is considered as a second-line agent in that, although some published cohort, retrospective, and subgroup studies show no harm there are others that suggest possible harm.

**Practical tip (2016)**
When digoxin is used, dosing should be adjusted according to renal function and potential drug interactions. Given analyses suggesting higher drug concentrations are associated with adverse
outcomes, maximum trough digoxin serum concentration of 1.2 ng/mL would be prudent. When digoxin is being used to treat patients with concomitant LV systolic dysfunction, its use should be dictated by the recommendations of the CCS Heart Failure Clinical Guidelines. When digoxin is being used to treat patients with concomitant LV systolic dysfunction, its use should be dictated by the recommendations of the CCS Heart Failure Clinical Guidelines.

**Recommendation 8 – Amiodarone for rate control therapy in exceptional cases (2010)**
We suggest that amiodarone for rate control should be reserved for exceptional cases in which other means are not feasible or are insufficient (Conditional Recommendation, Low Quality Evidence).

**Values and preferences (2010)**
Recommendations 6 to 9 recognize that selection of rate-control therapy needs to be individualized on the basis of the presence or absence of underlying structural heart disease, the activity level of the patient, and other individual considerations.

**Recommendation 9 – Dronedarone, not for patients with permanent AF (2012)**
We recommend that dronedarone not be used in patients with permanent AF nor for the sole purpose of rate control (Strong Recommendation, High Quality Evidence).

**Recommendation 10 – Dronedarone, not for patients with history of HF (2012)**
We recommend dronedarone not be used in patients with a history of heart failure or a left ventricular ejection fraction <0.40 (Strong Recommendation, Moderate Quality Evidence).

**Recommendation 11 – Dronedarone, to be used with caution with patients taking digoxin (2012)**
We suggest dronedarone be used with caution in patients taking digoxin (Conditional Recommendation, Moderate Quality Evidence).

**Values and preferences (2012)**
Recommendations 10-12 recognize that the mechanism(s) for the differences between the results of the ATHENA and the PALLAS trials have not yet been determined. These recommendations are based on the known differences between the 2 patient populations and are also informed by the results of the ANDROMEDA trial.

**Recommendation 12 – Beta-blockers as initial therapy in patients with MI or LV systolic dysfunction (2010)**
We recommend beta-blockers as initial therapy for rate control of AF or AFL in patients with myocardial infarction or left ventricular systolic dysfunction (Strong Recommendation, High Quality Evidence).

**Values and preferences (2010)**
This recommendation places a high value on the results of multiple randomized clinical trials reporting the benefit of beta-blockers to improve survival and decrease the risk of recurrent myocardial infarction and prevent new-onset heart failure following myocardial infarction, as well as the adverse effects of calcium channel blockers in the setting of heart failure.
Recommendation 13 – AVN ablation/pacemaker in symptomatic drug-refractory patients (2010)
We recommend AV junction ablation and implantation of a permanent pacemaker in symptomatic patients with uncontrolled ventricular rates during AF despite maximally tolerated combination pharmacologic therapy (Strong Recommendation, Moderate Quality Evidence).

Values and preferences (2010)
This recommendation places a high value on the results of many small randomized trials and one systematic review reporting significant improvements in QOL and functional capacity as well as a decrease in hospitalizations for AF following AV junction ablation in highly symptomatic patients.

*Figure S1 (Figure 3 from 2012 Update): Summary of recommendations for choice of rate-control agents for various conditions.*
Part 4 – Rhythm Management of AF

Recommendation 1 – Treatment of precipitating or reversible conditions (2010)
We recommend the optimal treatment of precipitating or reversible predisposing conditions of AF prior to attempts to restore or maintain sinus rhythm (Strong Recommendation, Low Quality Evidence).

Recommendation 2 – Rhythm control strategy for patients symptomatic on rate control therapy (2010)
We recommend a rhythm-control strategy for patients with AF or AFL who remain symptomatic with rate-control therapy or in whom rate-control therapy is unlikely to control symptoms (Strong Recommendation, Moderate Quality Evidence).

Figure S2 (Figure 3 from 2014 Update): Approach to rate and/or rhythm control of AF in patients presenting with symptomatic AF.

Recommendation 3 – Goal of rhythm control therapy (2010)
We recommend that the goal of rhythm-control therapy should be improvement in patient symptoms and clinical outcomes, and not necessarily the elimination of all AF (Strong Recommendation, Moderate Quality Evidence).
Values and preferences (2010)
Recommendations 1-3 place a high value on the decision of individual patients to balance relief of symptoms and improvement in QOL and other clinical outcomes with the potentially greater adverse effects of the addition of class I or class III antiarrhythmic drugs to rate-control therapy.

Recommendation 4 – Maintenance antiarrhythmic drugs first-line in patients with recurrent AF (2010)
We recommend use of maintenance oral antiarrhythmic therapy as first-line therapy for patients with recurrent AF in whom long-term rhythm control is desired (see Figures) (Strong Recommendation, Moderate Quality Evidence).

Figure S3 (Figure 4 from 2012 Update): Summary of recommendations for choice of rhythm-control therapy in patients with normal systolic left ventricular function and no history of congestive heart failure.
Figure S4 (Figure 5 from 2012 Update): Summary of recommendations for choice of rhythm-control therapy in patients with a history of congestive heart failure (current or remote) or left ventricular systolic dysfunction.

**Recommendation 5** – Avoid antiarrhythmic in patients with advanced sinus or AV node disease (2010)

We recommend that oral antiarrhythmic drug therapy should be avoided in patients with AF or AFL and advanced sinus or AV nodal disease unless the patient has a pacemaker or implantable defibrillator (Strong Recommendation, Low Quality Evidence).

**Recommendation 6** – AV blocking agent to be used along with a class I antiarrhythmic drug (2010)

We recommend that an AV blocking agent should be used in patients with AF or AFL being treated with a class I antiarrhythmic drug (eg, propafenone or flecainide) in the absence of advanced AV node disease (Strong Recommendation, Low Quality Evidence).

**Values and preferences (2010)**

Recommendations 4 to 6 place a high value on the decision of individual patients to balance relief of symptoms and improvement in QOL and other clinical outcomes with the potentially greater adverse effects of class I and class III antiarrhythmic drugs compared with rate-control therapy.


We recommend intermittent antiarrhythmic drug therapy (“pill in the pocket”) in symptomatic patients with infrequent, longer-lasting episodes of AF or AFL as an alternative to daily antiarrhythmic therapy (Strong Recommendation, Moderate Quality Evidence).

**Values and preferences (2010)**

This recommendation places a high value on the results of clinical studies demonstrating the efficacy and safety of intermittent antiarrhythmic drug therapy in selected patients.
**Recommendation 8 – Electrical or pharmacological cardioversion for sinus rhythm restoration (2010)**
We recommend electrical or pharmacologic cardioversion for restoration of sinus rhythm in patients with AF or AFL who are selected for rhythm-control therapy and are unlikely to convert spontaneously (Strong Recommendation, Low Quality Evidence).

**Recommendation 9 – Pre-treatment with antiarrhythmic drugs before electrical cardioversion (2010)**
We recommend pre-treatment with antiarrhythmic drugs prior to electrical cardioversion in patients who have had AF recurrence post cardioversion without antiarrhythmic drug pre-treatment (Strong Recommendation, Moderate Quality Evidence).

**Values and preferences (2010)**
Recommendations 8 and 9 place a high value on the decision of individual patients to pursue a rhythm-control strategy for improvement in QOL and functional capacity.

**Recommendation 10 – For symptomatic bradycardia, dual-chamber pacing (2010)**
We suggest that patients requiring pacing for the treatment of symptomatic bradycardia secondary to sinus node dysfunction, atrial or dual-chamber pacing be generally used for the prevention of AF (Conditional Recommendation, High Quality Evidence).

**Recommendation 11 – Pacemaker to be programmed to minimize ventricular pacing (2010)**
We suggest that, in patients with intact AV conduction, pacemakers be programmed to minimize ventricular pacing for prevention of AF (Conditional Recommendation, Moderate Quality Evidence).

**Values and preferences (2010)**
Recommendations 10 and 11 recognize a potential benefit of atrial or dual-chamber pacing programmed to minimize ventricular pacing to reduce the probability of AF development following pacemaker implantation.
Part 5 – Catheter Ablation of Atrial Fibrillation and Atrial Flutter

**Recommendation 1 – Catheter ablation in symptomatic drug-refractory patients (2014)**
We recommend catheter ablation of AF in patients who remain symptomatic following an adequate trial of antiarrhythmic drug therapy and in whom a rhythm control strategy remains desired. (Strong Recommendation, Moderate Quality Evidence).

**Values and Preferences (2014)**
This recommendation recognizes that failure of multiple antiarrhythmic drugs results in few alternative strategies if maintenance of sinus rhythm is preferred based on symptom burden reduction and quality of life improvement.

**Recommendation 2 – Catheter ablation as first-line therapy in highly selected patients (2014)**
We suggest catheter ablation to maintain sinus rhythm as first-line therapy for relief of symptoms in highly selected patients with symptomatic, paroxysmal atrial fibrillation (Conditional Recommendation, Moderate Quality Evidence).

**Values and Preferences (2014)**
This recommendation recognizes that individual patients may have a strong intolerance or aversion to antiarrhythmic drugs such that the risk of ablation is deemed warranted.

**Table S4 (Table 2 from 2014 Update): Balance of benefit to risk for catheter ablation in patients with symptomatic atrial fibrillation**

<table>
<thead>
<tr>
<th></th>
<th>Long-standing*</th>
<th>Persistent</th>
<th>Paroxysmal</th>
</tr>
</thead>
<tbody>
<tr>
<td>First line</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Failed first drug</td>
<td>-</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Failed second drug</td>
<td>+</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td>Failed multiple drugs</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
</tr>
</tbody>
</table>

+ Indicates balance of benefit to risk in favour of catheter ablation.
* Ongoing symptomatic atrial fibrillation ≥ 1 year.

**Recommendation 3 – Catheter ablation only by operators with expertise and high volumes (2014)**
We suggest that catheter ablation of AF should be performed by electrophysiologists with a high degree of expertise and high annual procedural volumes (Conditional Recommendation, Low Quality Evidence).

**Values and Preferences (2014)**
This recommendation recognizes that the risks of catheter ablation are directly related to operator experience and procedural volume at a given center. Although it is difficult to specify exact numerical values, the threshold seems to be 25-50 procedures/operator/year.

**Recommendation 4 – Curative catheter ablation as first-line therapy for typical atrial flutter (2010)**
We recommend curative catheter ablation for symptomatic patients with typical atrial flutter as first line therapy or as a reasonable alternative to pharmacologic rhythm or rate control therapy (Strong Recommendation, Moderate Quality Evidence).
**Values and preferences (2010)**
This recommendation recognizes the high efficacy, low complication rate of catheter ablation and low efficacy of pharmacologic therapy, whether rate or rhythm control. 20

**Recommendation 5 – Catheter ablation of accessory pathway (2010)**
In patients with evidence of ventricular preexcitation during AF, we recommend catheter ablation of the accessory pathway, especially if AF is associated with rapid ventricular rates, syncope, or a pathway with a short refractory period (Strong Recommendation, Low Quality Evidence).

**Values and preferences (2010)**
This recommendation places a high value on the prevention of sudden cardiac death in patients at high risk and a low value on the small complication rate of catheter ablation of the accessory pathway.

**Recommendation 6 - Exclude reentrant tachycardia in young patients with lone paroxysmal AF (2010)**
In young patients with lone, paroxysmal AF, we suggest an electrophysiological study to exclude a reentrant tachycardia as a cause of AF; if present, we suggest curative ablation of the tachycardia (Conditional Recommendation, Very Low Quality Evidence).

**Values and preferences (2010)**
This recommendation recognizes that supraventricular tachycardia can initiate AF when the substrate for AF is present and can be ablated with a high success rate and minimal risk.
Part 6 – Prevention of Stroke and Systemic Embolism in Atrial Fibrillation/Flutter

Recommendation 1 – Stratification of patients using a predictive index for stroke risk (2014)
We recommend that all patients with AF or AFL (paroxysmal, persistent or permanent), should be stratified using a predictive index for stroke risk (for example, the “CCS algorithm” based on the CHADS\textsuperscript{2} model) (Strong Recommendation, High Quality Evidence).

Values and preferences (2014)
Use of a modified version of the CHADS\textsuperscript{2} schema (the “CCS algorithm”) is recommended to facilitate the choice of appropriate antithrombotic therapy by incorporating the substantial risk of stroke conferred by age 65-74 to the well validated CHADS\textsuperscript{2} risk stratification scheme. However, it excludes female sex or vascular disease alone for the reasons detailed above.

Figure S5 (Figure 1 from 2016 Update): The simplified “CCS Algorithm” for decisions on which patients with atrial fibrillation (AF) or atrial flutter should receive oral anticoagulation (OAC) therapy.
**Recommendation 2 – OAC therapy for patients ≥ 65 years or CHADS\_2 ≥ 1 (2014)**

We recommend that OAC therapy be prescribed for most patients with age ≥ 65 years or CHADS\_2 ≥ 1 (the “CCS algorithm”) – see Figure 1. (Strong Recommendation, Moderate Quality Evidence) Values and preferences (2014) This recommendation places relatively greater weight on the absolute reduction of stroke risk with OACs compared to aspirin in patients aged >65 or with CHADS\_2 ≥ 1 and less weight on the increased risk of major hemorrhage with OACs compared to aspirin.

**Recommendation 3 – ASA for patients with no risks besides arterial vascular disease (2014)**

We suggest that ASA (81 mg/day) be prescribed for patients with none of the risks outlined in the “CCS algorithm” (age < 65 years and no CHADS\_2 risk factors) who have arterial vascular disease (coronary, aortic, or peripheral). (Conditional Recommendation, Moderate Quality Evidence)

**Values and preferences (2014)**

This recommendation for places greater weight on the inconvenience, costs and risks of major hemorrhage with OAC compared to ASA patients whose risk of stroke is relatively low versus the strokes prevented. The recommendation for aspirin rather than no antithrombotic therapy places greater weight on the strokes prevented in this low risk group and less weight on the risks of major bleeding.

**Recommendation 4 – No antithrombotic therapy for patients with no major risks (2014)**

We suggest no antithrombotic therapy for patients with none of the risks outlined in the “CCS algorithm” (age < 65 years and no CHADS\_2 risk factors) and free of arterial vascular disease (coronary, aortic, peripheral) (Conditional Recommendation, Low Quality Evidence).

**Values and preferences (2014)**

This recommendation places greater weight on the inconvenience, costs and risks (major hemorrhage) with both OAC and ASA compared to no antithrombotic therapy and relatively less weight on the strokes prevented in this group of patients whose risk of stroke is very low.

**Recommendation 5 – Most patients should receive NOAC (2014)**

We recommend that when OAC-therapy is indicated for patients with non-valvular AF, most patients should receive dabigatran, rivaroxaban, apixaban or edoxaban (when approved) in preference to warfarin (Strong Recommendation, High Quality Evidence).

**Values and preferences (2014)**

---

**Table S5 (Table 1 from 2014 AF Guidelines Companion): Definitions of Stroke Risk Factors**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congestive heart failure</td>
<td>Documented moderate to severe systolic dysfunction; signs and symptoms of heart failure with reduced ejection fraction; or recent decompensated heart failure that required hospitalization irrespective of ejection fraction</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Resting blood pressure &gt; 140 mm Hg systolic and/or &gt; 90 mm Hg diastolic on at least 2 occasions or current antihypertensive pharmacological treatment</td>
</tr>
<tr>
<td>Age 65</td>
<td>Age ≥ 65 years</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Fasting plasma glucose concentration ≥ 7.0 mmol/L (126 mg/dL) or treatment with oral hypoglycemic agents and/or insulin</td>
</tr>
<tr>
<td>Stroke/transient ischemic attack/peripheral embolism</td>
<td>Ischemic stroke: focal neurologic deficit of sudden onset diagnosed by a neurologist, lasting &gt; 24 hours, and caused by ischemia; Transient ischemic attack: focal neurologic deficit of sudden onset diagnosed by a neurologist, lasting &lt; 24 hours; Peripheral embolism: thromboembolism outside the brain, heart, eyes, and lungs, or pulmonary embolism (defined by the responsible physician)</td>
</tr>
<tr>
<td>Vascular disease</td>
<td>Coronary artery disease, peripheral artery disease, or aortic plaque</td>
</tr>
</tbody>
</table>
This recommendation places a relatively high value on the greater ease of use of the NOACs in comparison to warfarin, and the results of large RCTs showing that the NOACs are either non-inferior or superior to warfarin in stroke prevention; the drugs have no more major bleeding or less bleeding vs warfarin and especially less intracranial hemorrhage. The recommendation places less value on the shorter clinical experience, lack of a specific antidote, and lack of a simple test for intensity of anticoagulant effect with the NOACs. The preference for one of the NOACs over warfarin is less marked among patients already receiving warfarin with stable therapeutic INRs, no bleeding complications, and who are not requesting a change in OAC therapy.

**Recommendation 6 – Warfarin when mechanical valve, mitral stenosis or renal dysfunction** *(2014)*
We recommend that when OAC is indicated, warfarin be used rather than one of the NOACs for those patients with a mechanical prosthetic valve, those with rheumatic mitral stenosis and those with a CrCl of 15 - 30 mL/min (Strong Recommendation, Moderate Quality Evidence).

**Values and preferences** *(2014)*
This recommendation places high value on the evidence from one RCT of the inferiority of dabigatran compared to warfarin for the prevention of thromboemboli in patients with a mechanical prosthetic valve. It places relatively high value on the long experience and clinical reports of the use of warfarin in patients with rheumatic mitral stenosis and patients with CrCl 15 – 30 mL/min and the absence of such information for NOACs.
Table S6 (Table 5 from 2014 AF Guidelines Companion): Expert opinion survey regarding the clinical use of a NOAC in relation to the following commonly encountered scenarios: Would you consider NOAC use to be: (1) contraindicated or (2) not contraindicated (ie, reasonable to use) with the following valvular disorders?

<table>
<thead>
<tr>
<th>NOAC use is contraindicated</th>
<th>NOAC use is reasonable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical heart valves</td>
<td></td>
</tr>
<tr>
<td>- In any position (100% agreement)</td>
<td>Bioprosthetic heart valve</td>
</tr>
<tr>
<td>- Rheumatic mitral stenosis</td>
<td>- Aortic position (82% agreement)</td>
</tr>
<tr>
<td>- Mild (47% agreement)</td>
<td>- Mitral position (73% agreement)</td>
</tr>
<tr>
<td>- Moderate-severe (88% agreement)</td>
<td>Mitral annuloplasty</td>
</tr>
<tr>
<td>- After commissurotomy (42% agreement)</td>
<td>- With or without prosthetic ring (88% agreement)</td>
</tr>
<tr>
<td>Non-rheumatic mitral stenosis</td>
<td>Nonrheumatic mitral stenosis</td>
</tr>
<tr>
<td>- Moderate or severe (69% agreement)</td>
<td>- Mild (97% agreement)</td>
</tr>
<tr>
<td>Tricuspid regurgitation</td>
<td>- Mitral regurgitation</td>
</tr>
<tr>
<td>- Any severity (98% agreement)</td>
<td>- Mild (97% agreement)</td>
</tr>
<tr>
<td></td>
<td>- Moderate-severe (&gt;90% agreement)</td>
</tr>
</tbody>
</table>

NOAC, novel non-vitamin K antagonist.

Recommendation 7 – Patients who refuse OAC should receive ASA plus clopidogrel (2014)
We recommend that patients whose risk of stroke warrants OAC therapy, but who refuse any OAC, should receive ASA 81 mg/ day plus clopidogrel 75 mg/ day (Strong Recommendation, High Quality Evidence).

Values and preferences (2014)
This recommendation places high value on the superiority of the combination of ASA and clopidogrel over ASA alone in the ACTIVE-A trial. However, bleeding risk of combined antiplatelet therapy may not be very different from OAC monotherapy.

Recommendation 8– OAC therapy for highly selected patients with subclinical AF (2014)
We suggest that it is reasonable to prescribe OAC therapy for patients with age ≥ 65 years or CHADS₂ ≥ 1 ("CCS algorithm") who have episodes of SCAF lasting more than 24 hours, or for shorter episodes in high risk patients (such as those with a recent cryptogenic stroke) (Conditional Recommendation, Low Quality of Evidence).

Recommendation 9 – OAC for 3 weeks before and at least 4 weeks post cardioversion (2010)
We recommend that hemodynamically stable patients with AF or AFL for whom electrical or pharmacological cardioversion is planned should receive therapeutic OAC therapy for 3 weeks before and at least 4 weeks post cardioversion. Following attempted cardioversion:
a) If AF or AFL persists or recurs or if symptoms suggest that the presenting AF or AFL has been recurrent, the patient should have antithrombotic therapy continued as per the “CCS algorithm”.

b) If sinus rhythm is achieved and sustained for 4 weeks, the need for ongoing antithrombotic therapy should be based upon the risk of stroke and, in selected cases, expert consultation may be required (Strong Recommendation, Moderate Quality Evidence).

Recommendation 10 – Annual renal function assessment (2012)
We recommend that patients with AF who are receiving OAC should have their renal function assessed at least annually by measuring serum creatinine and calculating CrCl (Strong Recommendation, Moderate Quality Evidence) and should be regularly considered for the need for alteration of OAC drug and/or dose changes based on CrCl (Strong Recommendation, Moderate Quality Evidence).

Recommendation 11 – Antithrombotic therapy should relate to CrCl (2012)
For antithrombotic therapy of CKD patients, therapy should relate to CrCl as follows:

CrCl >30 mL/min: We recommend that such patients receive antithrombotic therapy according to their risk as determined by the “CCS algorithm” as detailed in recommendations for patients for patients with normal renal function (Strong Recommendation, High Quality Evidence).

CrCl 15-30 mL/min and not on dialysis: We suggest that such patients receive antithrombotic therapy according to their risk as determined by the “CCS algorithm” as for patients with normal renal function. The preferred agent for these patients is warfarin (Conditional Recommendation, Low Quality Evidence).

CrCl<15mL/min (on dialysis): We suggest that such patients not routinely receive either OAC (Conditional Recommendation, Low Quality Evidence) or ASA for stroke prevention in AF (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2016, updated from 2012)
Recommendation 11 places a relatively higher value on prevention of ischemic stroke than on bleeding complications associated with antithrombotic therapy, as well as the limited data available for new OACs in CKD patients. They also place a relatively higher weight on observational data linking warfarin and ASA use with mortality in patients on dialysis, and relatively lower weight on the potential for these agents to prevent ischemic stroke. Patients on renal dialysis who have atrial fibrillation continue to be at high risk of both stroke and major bleeding complications. This population has been largely excluded from clinical trials evaluating stroke prevention therapies, and there have been no substantial new advances in the management of these individuals. Such studies are being planned, but until they can be completed, clinicians must continue to balance the risks of stroke against the risk of bleeding complications.

Practical tip (2012)
No antithrombotic therapy may be appropriate for some patients with CrCl 15-30 mL/min (not on dialysis), with a stronger preference for avoiding bleeding complications than preventing ischemic stroke.

Practical tip (2016, updated from 2010)
Therapy with OACs or antiplatelet drugs may be appropriate for some patients with AF and CrCl<15 mL/min (on dialysis) in whom there is a stronger preference to avoid ischemic stroke despite uncertain benefit and likely greater bleeding risk.
Table S7 (Table 6 from 2014 AF Guidelines Companion): Recommendations for dosage of oral anticoagulants based on renal function

<table>
<thead>
<tr>
<th>CrCl</th>
<th>Warfarin</th>
<th>Dabigatran</th>
<th>Rivaroxaban</th>
<th>Apixaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrCl &gt; 50 mL/min</td>
<td>Dose adjusted for INR 2.0-3.0</td>
<td>150 mg bid</td>
<td>20 mg daily</td>
<td>5 mg bid</td>
</tr>
<tr>
<td>CrCl 30-49 mL/min</td>
<td>Dose adjusted for INR 2.0-3.0</td>
<td>Consider 110 mg bid in preference to 150 bid</td>
<td>15 mg daily</td>
<td>5 mg bid (consider 2.5 mg bid)</td>
</tr>
<tr>
<td>CrCl 15-29 mL/min</td>
<td>No RCT data</td>
<td>No RCT data</td>
<td>No RCT data</td>
<td>Very limited RCT data</td>
</tr>
<tr>
<td>CrCl &lt; 15 mL/min (or the patient is dialysis-dependent)</td>
<td>No RCT data</td>
<td>No RCT data</td>
<td>No RCT data</td>
<td>No RCT data</td>
</tr>
</tbody>
</table>

ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; bid, twice daily; CrCl, creatinine clearance; INR, international normalized ratio; RCT, randomized clinical trial.

1 Consider dabigatran 110 mg oral bid if age > 75 years.
2 Dose-adjusted warfarin has been used, but data regarding safety and efficacy are conflicting.
3 The ARISTOTLE trial did include patients with a CrCl as low as 25 mL/min, but this was a very small number of patients (1.5% of patients in the trial).
4 Dose-adjusted warfarin has been used, but data regarding safety and efficacy are conflicting and might lean toward causing harm.
5 No published studies support a dose for this level of renal function; product monographs suggest the drug is contraindicated for this level of renal function.

Recommendation 12 – LAA closure devices to be used only in research and, exceptional cases (2014)
We suggest these non-approved LAA closure devices not be used, except in research protocols or in systematically documented use protocols in patients who are at high risk of stroke (CHADS2 ≥ 2) and yet antithrombotic therapy is precluded (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2014)
This recommendation places relatively great weight on the absence of RCTs showing clear benefit to risk in favor of these devices and on the need for further research and careful case series.

Recommendation 13 – Acute management of stroke patients as per AHA/ASA guidelines (2010)
We recommend that patients with AF or AFL who experience a stroke be managed acutely according to the published guidelines of the American Heart and American Stroke Associations (Strong Recommendation, Moderate Quality Evidence).

Recommendation 14 – Hemorrhage on OAC to be managed per AACP guidelines (2010)
We suggest that patients with AF or AFL who experience hemorrhage while on OAC be managed according to the published practice guidelines of the American College of Chest Physicians (Conditional Recommendation, Low Quality Evidence).

Recommendation 15 – Idarucizimab for emergency reversal of dabigatran's anticoagulant effect (2016)
We recommend administering idarucizimab for emergency reversal of dabigatran's anticoagulant effect in patients with uncontrollable or potentially life-threatening bleeding and/or in patients requiring urgent surgery for which normal hemostasis is necessary (Strong Recommendation, Moderate Quality Evidence).

Values and Preferences
This recommendation places relatively greater value on the ability of idarucizimab to reverse coagulation parameters indicative of dabigatran’s effect, its potential to decrease bleeding-related outcomes and risks of urgent surgery and its safety and tolerability profile, and less value on the absence of a control group in the RE-VERSE AD trial and the cost of the drug.
Practical Tips (2016)

In the acute, life-threatening bleeding situation where standard resuscitation (such as local measures, transfusion, etc) is not anticipated to be sufficient (e.g. ICH), or in the situation where it has not stabilized the patient, idarucizumab, should be administered as soon as possible. Although dilute thrombin time and ecarin clotting time were used to identify the presence of dabigatran in REVERSE-AD, these tests are not widely available. Thrombin time (TT) and activated partial thromboplastin time (aPTT) are widely available and can qualitatively identify the presence of active dabigatran in a patient, however obtaining these tests should not delay the administration of idarucizumab. In many instances of life-threatening bleeding, clinicians have to base a treatment decision on a history of dabigatran use rather than laboratory evidence. Renal function and timing of the last dose of dabigatran provide key information regarding the likely extent of remaining dabigatran effect. The timing of surgery may permit clinicians to obtain coagulation parameters like stat TT or aPTT to identify patients who no longer have dabigatran present, and who would be unlikely to benefit from idarucizumab. No dose adjustment for idarucizumab is required in patients with renal impairment. In some patients, coagulation parameters may rise between 12-24 hours after initial administration of idarucizumab, possibly reflecting redistribution of extravascular dabigatran into the intravascular space. Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. OAC should be reintroduced as soon as medically appropriate.
Part 7 – Management of Antithrombotic Therapy in patients with concomitant AF and CAD

General recommendations regarding antithrombotic therapy in the context of concomitant AF and CAD (asymptomatic, stable CAD, elective PCI, NSTEMI or STEMI):

Recommendation 1 – Antithrombotic therapy based on a balanced assessment of a patient’s risk of stroke (2016)
We recommend that patients who have concomitant AF and CAD receive a regimen of antithrombotic therapy that is based on a balanced assessment of their risks of stroke, of a coronary event and of hemorrhage associated with use of antithrombotic agents (Strong Recommendation, High Quality Evidence).

Recommendation 2 – Most patients with an indication for OAC in the presence of CAD should receive a NOAC (2016)
When OAC is indicated in the presence of CAD, we suggest a NOAC in preference to warfarin for non-valvular AF (Conditional Recommendation, Low Quality Evidence).

Practical tip (2016, updated from 2014)
When CAD is present, some expert clinicians prefer a combination of a NOAC and aspirin rather than NOAC alone in preference to warfarin alone for patients perceived to be at higher risk of coronary events and low risk of major bleeding and may choose a NOAC alone as a reasonable option in those with average to lower risk of coronary events and higher risk of bleeding.

Values and preferences (2016, updated from 2014)
The suggestion for use of a NOAC rather than warfarin places relatively greater weight on the ease of use of NOACs versus warfarin and on the data from RCTs of NOACs versus warfarin for NVAF, showing equal or greater reduction of stroke, equal or less major bleeding, less intracranial bleeding and no net increase in CAD outcomes. It places relatively less weight on the absence of long-term data on the effect of NOACs on coronary outcomes as opposed to the data for efficacy of warfarin.

Practical tip (2016)
In general, the recommended doses of NOACs are the usual doses studied in the RCTs of NVAF. For patients requiring combinations of antiplatelet and OAC agents for concomitant AF and CAD, we suggest that measures be employed to reduce the risk of bleeding, including careful consideration of HAS-BLED risk factors and vigorous efforts to mitigate them; specific measures during invasive procedures (radial access, small-diameter sheaths, early sheath removal from femoral site and minimized use of acute procedural anti-thrombotic therapies); consideration of routine proton pump inhibitor (PPI); avoidance of prasugrel and ticagrelor in conjunction with OAC; the use of warfarin in the lower INR range; consideration of the lower effective doses of NOACs; and delaying non-urgent catheterization until there is clarity about coagulation status and renal function. If the risk of restenosis is relatively low, the option of a BMS rather than a second generation DES should be considered.
For patients with AF, with an indication for primary CAD prevention or stable CAD/arterial vascular disease (peripheral vascular disease or aortic plaque), the selection of antithrombotic therapy should be based on their risk of stroke as follows (Figure 2, from 2016 update):

**Recommendation 3 – No antithrombotic therapy for patients with no evidence of manifest CAD/vascular disease (2016)**

If the patient has no evidence of CAD/vascular disease and is aged <65 years with no CHADS2 risk factors, we suggest no antithrombotic therapy for stroke prevention (Conditional Recommendation, Moderate Quality Evidence).

**Recommendation 4 – ASA for patients with no risks besides CAD/arterial vascular disease (2016)**

If the patient has stable CAD/vascular disease and is aged <65 years with no CHADS2 risk factors, we suggest aspirin 81 mg daily (Conditional Recommendation, Moderate Quality Evidence).

**Recommendation 5 – OAC therapy for patients ≥ 65 years or CHADS2 ≥ 1 (2016)**

If the patient has stable CAD/vascular disease and is aged ≥ 65 or the CHADS2 ≥ 1, we recommend OAC therapy alone (Strong Recommendation, High Quality Evidence).

For patients with AF and recent elective PCI, the selection of antithrombotic therapy should be based on their risk of stroke as follows (Figure 3, from 2016 update):

**Recommendation 6 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

If the patient is aged <65 years with no CHADS2 risk factors, we recommend aspirin 81 mg daily indefinitely (Strong Recommendation, High Quality evidence).

**Recommendation 7 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

If the patient is aged <65 years with no CHADS2 risk factors, we recommend clopidogrel 75 mg daily for 12 months in addition to aspirin (Strong Recommendation, High Quality Evidence).

**Recommendation 8 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

If the patient is aged <65 years with no CHADS2 risk factors, we recommend that in patients receiving a bare-metal stent who are unable to tolerate clopidogrel for 12 months (eg, increased risk of bleeding or scheduled noncardiac surgery), the minimum duration of therapy should be 1 month (Strong Recommendation, High-Quality Evidence). We suggest in patients at very high risk of bleeding, the minimum duration of treatment may be 2 weeks (Conditional Recommendation, Low-Quality Evidence).

**Recommendation 9 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

If the patient is aged <65 years with no CHADS2 risk factors, we suggest that in patients receiving a second generation DES who are unable to tolerate clopidogrel for 12 months (eg, increased risk of bleeding or scheduled noncardiac surgery), the minimum duration of therapy may be 3 months (Conditional Recommendation, Low-Quality Evidence).
**Recommendation 10 (2016)**

*If the patient is aged ≥ 65 years or the CHADS\(_2\) score ≥ 1, we suggest that clopidogrel 75 mg/d and OAC be given, without concomitant ASA, for 12 months post-PCI (Conditional Recommendation, Moderate-Quality Evidence), to be followed by OAC alone (Strong Recommendation, High-Quality Evidence).*

**Practical Tip (2016)**

Some patients who are at high risk of stent thrombosis and whose risk of major bleeding is acceptable may continue OAC + clopidogrel for longer than 12 months post ACS, whereas those at particularly high risk of major bleeding may have their clopidogrel discontinued earlier than 12 months and continue to receive only OAC.

**For patients with AF, in association with Non-ST Elevation Acute Coronary Syndrome (NSTEMACS) or ST Segment Elevation Myocardial Infarction (STEMI), the selection of antithrombotic therapy should be based on their risk of stroke as follows (Figure 4, from 2016 update):**

**Recommendation 11 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

*If the patient is aged<65 years with no CHADS\(_2\) risk factors, we recommend aspirin 81 mg daily indefinitely (Strong Recommendation, High Quality Evidence).*

**Recommendation 12 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

*If the patient is aged<65 with no CHADS\(_2\) risk factors and no PCI is undertaken, we recommend ticagrelor 90 mg bid for 12 months in addition to ASA in patients with moderate to high risk NSTEMACS (defined as ≥ 2 of: 1) ischemic ST changes on ECG, 2) positive biomarkers or 3) any 1 of the following: age ≥ 60 yr, previous MI or CABG, CAD > 50% stenosis in ≥ 2 vessels, previous ischemic stroke, DM, PAD, or CKD) and in most STEMI patients (Strong Recommendation, High Quality Evidence).*

**Recommendation 13 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

*If the patient is aged<65 with no CHADS\(_2\) risk factors and PCI is undertaken, we recommend clopidogrel 75 mg once daily in addition to ASA for 12 months in lower risk patients and in those judged unsuitable for ticagrelor or when this agent is not available (Strong Recommendation, High Quality Evidence).*

**Recommendation 14 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)**

*If the patient is aged<65 years with no CHADS\(_2\) risk factors and PCI is undertaken, we recommend ticagrelor 90 mg bid for 12 months in addition to ASA (Strong Recommendation, High Quality Evidence).*


*If the patient is aged<65 years with no CHADS\(_2\) risk factors and PCI is undertaken, as an alternative to ticagrelor, we recommend prasugrel 10 mg daily for 12 months in addition to aspirin in P2Y12-naïve patients after their coronary anatomy has been defined and PCI planned. Except in patients with a high probability of undergoing PCI, we recommend delaying prasugrel until the coronary anatomy has been defined and avoiding prasugrel in patients not having PCI (Strong Recommendation, High Quality Evidence).*
Recommendation 16 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)
*If the patient is aged<65 years with no CHADS<sup>2</sup> risk factors and PCI is undertaken,* we suggest that for patients prescribed prasugrel and aged ≥ 75 years or weight < 60 kg consideration be given to prasugrel 5 mg daily (Conditional Recommendation, Low Quality Evidence). We recommend avoiding prasugrel in patients with previous TIA or stroke (Strong Recommendation, Moderate Quality Evidence).

Recommendation 17 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)
*If the patient is aged<65 years with no CHADS<sup>2</sup> risk factors and PCI is undertaken,* in patients who are not eligible for ticagrelor or prasugrel, we recommend clopidogrel 75 mg once daily for 12 months in addition to aspirin, and that a dose of 150 mg daily be considered for the first 6 days following PCI (Strong Recommendation, High Quality Evidence).

Recommendation 18 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)
*If the patient is aged<65 years with no CHADS<sup>2</sup> risk factors and PCI is undertaken,* we suggest that some patients with NSTEACS or STEMI, who have undergone PCI, who are at higher risk of stent thrombosis and whose risk of major bleeding is acceptable, may be considered for an ADP receptor antagonist (clopidogrel, prasugrel or ticagrelor) plus aspirin for longer than 12 months post NSTEACS or STEMI (Conditional Recommendation, Low Quality Evidence).

Recommendation 19 (2016, adapted from CCS 2012 Antiplatelet Therapy Guidelines)
*If the patient is aged<65 years with no CHADS<sup>2</sup> risk factors and PCI is undertaken,* we suggest that some patients with NSTEACS or STEMI, at particularly high risk of major bleeding, may have their ADP receptor antagonist discontinued earlier than 12 months post NSTEACS or STEMI and continue to receive only aspirin (Conditional Recommendation, Low Quality Evidence).

Recommendation 20 (2016)
*If the patient is aged≥65 or the CHADS<sup>2</sup>≥1 and no PCI is undertaken,* we suggest the combination of clopidogrel 75 mg daily (rather than prasugrel or ticagrelor) and OAC be given, without concomitant ASA, for 12 months, to be followed by OAC alone (Conditional Recommendation, Low Quality Evidence).

Recommendation 21 (2016)
*If the patient is aged≥65 or the CHADS<sup>2</sup>≥1 and PCI is undertaken,* we suggest the combination of aspirin 81 mg daily and clopidogrel 75 mg daily and OAC (TT) for 3-6 months (duration depending on the perceived risks of coronary thrombosis and major bleeding). After 3-6 months we suggest the combination of clopidogrel and OAC to be continued until 12 months post-ACS, to be followed by OAC alone (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2016)
The suggestion of TT for the first 3-6 months places greater weight on more reduction of coronary events (versus OAC + clopidogrel) and on more SSE prevented (versus DAPT) but less weight on the increased risk of major bleeding. The balance of stroke/systemic embolus prevented and major bleeds caused could be judged as appropriate only for patients with a higher risk of stroke (e.g. CHADS<sup>2</sup>≥2).

Practical tip (2016)
Some patients who are at high risk of stent thrombosis and whose risk of major bleeding is acceptable may continue the combination of OAC and clopidogrel for longer than 12 months post ACS.

Practical tip (2016)
Some patients at particularly high risk of major bleeding may have their clopidogrel discontinued earlier than 12 months and continue to receive only OAC.

**Practical tip (2016)**

Some clinicians may prefer the combination of clopidogrel and OAC beginning from the time of PCI, placing more weight on the reduced bleeding and no increase of thrombotic events compared to TT in the WOEST trial and less value on the fact that only 25% of patients in this trial had PCI for ACS. A combination of aspirin and ticagrelor, or aspirin and prasugrel, or aspirin and clopidogrel may also be used in preference to TT for some patients with CHADS$_2$=1 at the lower end of the stroke risk spectrum (e.g. isolated hypertension), reserving TT or OAC + clopidogrel for patients at higher stroke risk.
Figure S6 (Figure 2 from 2016 Update): A summary of our recommendations for the management of antithrombotic therapy in patients with concomitant atrial fibrillation (AF) and an indication for primary CAD prevention or stable coronary artery disease (CAD) / vascular disease.

For patients with AF with an indication for primary CAD prevention or stable CAD/arterial vascular disease:

- Age < 65 and CHADS$_2$ = 0
  No CAD / vascular disease
  *No antithrombotic therapy
- Age < 65 and CHADS$_2$ = 0
  Stable CAD / vascular disease
  ASA
- Age ≥ 65 or CHADS$_2$ ≥ 1
  Stable CAD / vascular disease
  OAC* alone

* A NOAC is preferred over warfarin for non-valvular AF
† Primary CAD prevention with ASA may be considered in selected high-risk patients
Figure S7 (Figure 3 from 2016 Update): A summary of our recommendations for the management of antithrombotic therapy in patients with atrial fibrillation (AF) and recent percutaneous coronary intervention (PCI)

For patients with AF and recent elective PCI

- Age < 65 and CHADS₂ = 0
  - ASA + Clopidogrel for 12 months
  - ASA alone after 12 months

- Age ≥ 65 or CHADS₂ ≥ 1
  - OAC* + Clopidogrel for 12 months
  - OAC* alone after 12 months

* A NOAC is preferred over warfarin for non-valvular AF
Figure S8 (Figure 4 from 2016 AF Update): A summary of our recommendations for the management of antithrombotic therapy in patients with atrial fibrillation (AF) in association with Non ST-Elevation Acute Coronary Syndrome (NSTEMI) and ST-elevation Myocardial Infarction (STEMI).
Part 8 – Management of Recent Onset Atrial Fibrillation and Flutter in the Emergency Department

Recommendation 1 – Rate or rhythm control therapy for patients with recent onset AF/AFL (2010)
We recommend that in stable patients with recent-onset AF/AFL, a strategy of rate control or rhythm control could be selected (Strong Recommendation, High Quality Evidence).

Values and preferences (2010)
This recommendation places a high value on the randomized controlled trials investigating rate control as an alternative to rhythm control for AF/AFL, recognizing that these trials did not specifically address the ED environment.

Recommendation 2 – Hemodynamically stable patients with AF/AFL <48 hours (2010)
In hemodynamically stable patients with AF/AFL of known duration <48 hours in whom a strategy of rhythm control has been selected:

a) We recommend that rate-slowing agents alone are acceptable while awaiting spontaneous conversion (Strong Recommendation, Moderate Quality Evidence).

b) We recommend that synchronized electrical cardioversion or pharmacologic cardioversion may be used when a decision is made to cardiovert patients in the emergency department. See Table for drug recommendations (Strong Recommendation, Moderate Quality Evidence).

c) We suggest that antiarrhythmic drugs may be used to pretreat patients before electrical cardioversion in ED in order to decrease early recurrence of AF and to enhance cardioversion efficacy (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2010)
These recommendations place a high value on determination of the duration of AF/AFL as a determinant of stroke risk with cardioversion. Also, individual considerations of the patient and treating physician are recognized in making specific decisions about method of cardioversion.

We recommend that electrical cardioversion may be conducted in the ED with 150-200 joules biphasic waveform as the initial energy setting (Strong Recommendation, Low Quality Evidence).

Values and preferences (2010)
This recommendation places a high value on the avoidance of repeated shocks and the avoidance of ventricular fibrillation that can occur with synchronized cardioversion of AF at lower energy levels. It is recognized that the induction of VF is a rare but easily avoidable event.

Recommendation 4 – WPW/rapid response, DC cardioversion for hemodynamically unstable (2010)
We recommend, in patients with rapid ventricular preexcitation during AF (Wolff-Parkinson-White syndrome):

a) Urgent electrical cardioversion if the patient is hemodynamically unstable (Strong Recommendation, Low Quality Evidence).

b) Intravenous antiarrhythmic agents procainamide or ibutilide in stable patients (Strong Recommendation, Low Quality Evidence).
c) AV nodal blocking agents (digoxin, calcium channel blockers, beta-blockers, adenosine) are contraindicated (Strong Recommendation, Low Quality Evidence).

**Values and preferences (2010)**
These recommendations place a high value on avoidance of the degeneration of preexcited AF to ventricular fibrillation. It is recognized that degeneration can occur spontaneously or it can be facilitated by the administration of specific agents that in the absence of ventricular preexcitation would be the appropriate therapy for rate control of AF.

**Recommendation 5 – Lower stroke risk and AF < 48 hours, may undergo cardioversion (2014)**
For patients with no high-risk factors for stroke (recent stroke or TIA within 6 months; rheumatic heart disease; mechanical valve) and clear AF-onset within 48 hours or therapeutic OAC therapy for ≥3 weeks, we recommend that they may undergo cardioversion in the ED without immediate initiation of anticoagulation. Following attempted or successful cardioversion, antithrombotic therapy should be initiated as per the CCS algorithm. (Strong recommendation, Moderate Quality Evidence)

**Values and preferences (2014)**
This recommendation places high value on the symptomatic improvement with immediate cardioversion for those at very low risk of stroke.

**Recommendation 6 – High stroke risk: rate control and OAC therapy 3 weeks precardioversion (2014)**
For patients at high risk of stroke with cardioversion (not receiving therapeutic OAC therapy for ≥3 weeks with any of the following: AF episode duration not clearly <48 hours; stroke or TIA within 6 months; rheumatic heart disease; mechanical valve), we recommend optimized rate-control and therapeutic OAC for 3 weeks before and at least 4 weeks after cardioversion. (Strong Recommendation, Moderate Quality Evidence)

**Values and preferences (2014)**
These recommendations place a high value on minimizing stroke risk by a strategy of rate control, appropriate anticoagulation and delayed cardioversion and a lower value on symptomatic improvement associated with immediate cardioversion.

**Recommendation 7 – High stroke risk and cardioversion after TEE (2014)**
We suggest that patients at high risk of stroke (not receiving therapeutic OAC therapy for ≥3 weeks with any of the following: AF episode duration not clearly <48 hours; stroke or TIA within 6 months; rheumatic heart disease; mechanical valve) may undergo cardioversion guided by transesophageal echocardiography with immediate initiation of intravenous or low molecular weight heparin prior to cardioversion followed by therapeutic OAC for at least 4 weeks post cardioversion. (Conditional Recommendation, Moderate Quality Evidence)

**Values and preferences (2014)**
This recommendation places a high value on the symptomatic improvement with immediate cardioversion as well as the reduced risk of peri-cardioversion stroke conferred by a transesophageal echocardiogram demonstrating an absence of intracardiac thrombus. Lower value is placed on the small risks associated with the TEE.
Recommendation 8 – Hemodynamic instability: consider immediate DC cardioversion (2014)
For patients whose recent-onset AF/AFL is the direct cause of instability with hypotension, acute coronary syndrome, or florid pulmonary edema, we recommend that immediate electrical cardioversion be considered with immediate initiation of intravenous or low molecular weight heparin prior to cardioversion followed by therapeutic OAC for 4 weeks afterwards (unless AF-onset was clearly within 48 hours or the patient has received therapeutic OAC for >3 weeks) followed by therapeutic OAC for at least 4 weeks post cardioversion (Strong recommendation, Low Quality Evidence).

Values and preferences (2014)
This recommendation places a high value on immediately addressing instability by attempting cardioversion, and a lower value on reducing the risk of cardioversion-associated stroke with a period of anticoagulation pre-cardioversion.

Recommendation 9 – Hospital admission for decompensated HF or myocardial ischemia (2010)
We recommend hospital admission for highly symptomatic patients with decompensated heart failure or myocardial ischemia (Strong Recommendation, Low Quality Evidence).

Recommendation 10 - Admission for highly symptomatic patients with unachievable rate control (2010)
We suggest limiting hospital admission to highly symptomatic patients in whom adequate rate control cannot be achieved (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2010)
Recommendation 9 and 10 place a high value on the need for monitoring of the response to therapy and its reassessment, as well as ancillary investigation and treatment not available in the ED in patients with complex medical conditions associated with AF/AFL. A lower value is placed on the attendant costs of admission to hospital in patients with complex medical conditions associated with AF/AFL.

Recommendation 11 – Antiarrhythmic drug therapy post-cardioversion (2010)
We suggest that after conversion to sinus rhythm has been achieved, whether antiarrhythmic drug therapy is indicated should be based on the estimated probability of recurrence and the symptoms during AF. Long-term therapy will need to be determined by an appropriate outpatient consultation (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2010)
This recommendation places a high value on minimizing the risk of infrequent but serious side effects associated with long-term antiarrhythmic drugs. A high value is also placed on the appropriate use of specialty care to make patient-specific decisions to minimize these risks. A lower value is placed on the avoidance of symptoms associated with subsequent episodes of AF/AFL.
Figure S9 (Figure 2 from 2014 Update): Decision algorithm for management of oral anticoagulation (OAC) therapy for patients who present to the emergency department (ED) with recent-onset atrial fibrillation (AF) requiring rate control or cardioversion (CV) in the ED.

Table S8 (Table 2 from 2010): Recommended intravenous drugs for heart rate control in the ED

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diltiazem*</td>
<td>0.25 mg/kg IV bolus over 10 min; repeat at 0.35 mg/kg IV</td>
<td>Hypotension, bradycardia</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>2.5-5 mg IV bolus over 2 min; up to 3 doses</td>
<td>Hypotension, bradycardia</td>
</tr>
<tr>
<td>Verapamil*</td>
<td>0.075-0.15 mg/kg over 2 min</td>
<td>Hypotension, bradycardia</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.25 mg IV each 2 h; up to 1.5 mg</td>
<td>Bradycardia, digitalis toxicity</td>
</tr>
</tbody>
</table>

*Calcium-channel blockers should not be used in patients with heart failure/left ventricular dysfunction.

Table S9 (Table 3 from 2010): Recommended Drugs for Pharmacological Conversion in the ED

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Efficacy</th>
<th>Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class IA</td>
<td>Procaainamide</td>
<td>++</td>
<td>5% hypotension</td>
</tr>
<tr>
<td></td>
<td>15-17 mg/kg IV over 60 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class IC*</td>
<td>Propafenone</td>
<td>+++</td>
<td>Hypotension, 1:1 flutter, bradycardia</td>
</tr>
<tr>
<td></td>
<td>450-600 mg PO</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td></td>
<td>300-400 mg PO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class III</td>
<td>Flecainide</td>
<td>++</td>
<td>2-3% Torsades de pointes</td>
</tr>
<tr>
<td></td>
<td>1-2 mg IV over 10-20 min</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pre-treat with MgSO4 1-2 g IV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Class IC drugs should be used in combination with AV nodal blocking agents (beta-blockers or calcium-channel inhibitors). Class IC drugs should also be avoided in patients with structural heart disease.
Part 9 – Surgical Therapy for Atrial Fibrillation

Recommendation 1 – Surgical AF ablation in association with cardiac surgery (2016, updated from 2010)
We suggest that a surgical AF ablation procedure should be considered in association with mitral valve, aortic valve or CABG surgery in patients with AF, when the likelihood of success is deemed to be high, the additional risk is low and sinus rhythm is expected to achieve substantial symptomatic benefit (Conditional Recommendation, Moderate Quality Evidence).

Values and preferences (2016, updated from 2010)
This recommendation recognizes that individual institutional experience and patient considerations best determine for whom the surgical procedure is performed. Importantly, the symptomatic benefit of sinus rhythm needs to be balanced with the attendant risks of ablation surgery, including the need for permanent pacing. This recommendation also recognizes that LA endocardial access is not routinely required for aortic or coronary surgery; limiting ablation to newer epicardial approaches.

Recommendation 2 – Asymptomatic lone AF, not to be considered for surgical therapy (2010)
We recommend that patients with asymptomatic lone AF, in whom AF is not expected to affect cardiac outcome, should not be considered for surgical therapy for AF (Strong Recommendation, Low Quality Evidence).

Values and preferences (2010)
This recommendation recognizes that patients with lone AF are at low risk for stroke or other adverse cardiovascular outcomes. Thus, elimination of AF in the absence of a high number of symptoms is unlikely to result in an improvement in quality of life.

Recommendation 3 – Closure of the left atrial appendage as part of surgical ablation of AF associated with cardiac surgery (2016, updated from 2010)
In patients with AF, we suggest that closure (excision or obliteration) of the LAA should be considered as part of the surgical ablation of AF associated with mitral, aortic valve or coronary artery bypass surgery if this does not increase the risk of the surgery (Conditional Recommendation, Low Quality Evidence).

Values and Preferences (2016, updated from 2010)
This recommendation places a high value on the potential for stroke reduction and a lower value on loss of atrial transport-function with LAA-closure. It places less value on the need to continue OAC even after LAA surgical excision.

Recommendation 4 – Continue OAC following surgical AF ablation per risk factors (2010)
We recommend that oral anticoagulant therapy be continued following surgical AF ablation in patients with any risks identified by the new “CCS algorithm” (Strong Recommendation, Moderate Quality Evidence).
Recommendation 5 – Continue OAC following surgical AF ablation for all MVRs (2010)

We suggest that oral anticoagulant therapy be continued following surgical AF ablation in patients who have undergone mechanical or bioprosthetic mitral valve replacement (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2010)
Recommendations 6 and 7 place a high value on minimizing the risk of stroke and a lower value in the utility of long-term monitoring to document the absence of AF.
Part 10 – Prevention and Treatment of Atrial Fibrillation following Cardiac Surgery

Recommendation 1 - Beta-blockers to be continued through the operative procedure (2010)
We recommend that patients who have been receiving a beta-blocker before cardiac surgery have that therapy continued through the operative procedure in the absence of the development of a new contraindication (Strong Recommendation, High Quality Evidence).
We suggest that patients who have not been receiving a beta-blocker before cardiac surgery have beta-blocker therapy initiated immediately after the operative procedure in the absence of a contraindication (Conditional Recommendation, Low Quality Evidence).

Values and preferences (2010)
These recommendations place a high value on reducing postoperative AF and a lower value on adverse hemodynamic effects of β-blockade during or after cardiac surgery. It is also noted that inherent to a strategy of prophylaxis, a number of patients will receive beta-blocker therapy without personal benefit.

Recommendation 2 – Amiodarone for patients with contraindications to beta-blockers (2010)
We recommend that patients who have a contraindication to beta-blocker therapy before or after cardiac surgery be considered for prophylactic therapy with amiodarone to prevent postoperative AF (Strong Recommendation, High Quality Evidence).

Values and preferences (2010)
This recommendation places a high value on minimizing the patient population exposed to the potential adverse effects of amiodarone and a lower value on data suggesting that amiodarone is more effective than beta-blockers for this purpose.

Recommendation 3 – Consider IV magnesium, colchicine, biatrial pacing when beta-blocker and amiodarone contraindicated (2016, updated from 2010)
We suggest that patients who have a contraindication to beta-blocker therapy and to amiodarone before or after cardiac surgery be considered for prophylactic therapy to prevent POAF with intravenous magnesium (Conditional Recommendation, Low Quality Evidence) or colchicine (Conditional Recommendation, Low Quality of Evidence) or with biatrial pacing (Conditional Recommendation, Low Quality of Evidence).

Values and preferences (2016, updated from 2010)
This recommendation places a high value on preventing POAF using novel therapies that are supported by lower-quality data; with a higher value on the lower probability of adverse effects from magnesium versus colchicine. The use of biatrial pacing needs to be individualized by patient and institution, as the potential for adverse effects may outweigh benefit based on local expertise.

Recommendation 4 – High risk and sotalol or combination prophylaxis (2010)
We suggest that patients at high risk of postoperative AF receive prophylactic therapy to prevent postoperative AF such as sotalol or combination therapy including ≥2 of a beta-blocker, amiodarone, intravenous magnesium, or biatrial pacing (Conditional Recommendation, Low- to Moderate Quality Evidence).

Values and preferences (2010)
This recommendation recognizes that data confirming the superiority of combinations of prophylactic therapies are sparse.

**Recommendation 5 - Consideration of OAC for postoperative AF >72 hours (2010)**
We suggest that consideration be given to anticoagulation therapy if postoperative continuous AF persists for >72 hours. This consideration will include individualized assessment of the risks of a thromboembolic event and the risk of postoperative bleeding (Conditional Recommendation, Low Quality Evidence).

**Values and preferences (2010)**
This recommendation places a higher value on minimizing the risk of thromboembolic events and a lower value on the potential for postoperative bleeding. Because the risk of postoperative bleeding decreases with time, the benefit-to-risk ratio favours a longer period without anticoagulation in the postoperative setting than that suggested in other settings.

**Recommendation 6 - Temporary epicardial pacing electrode wires at surgery (2010)**
We recommend that temporary ventricular epicardial pacing electrode wires be placed at the time of cardiac surgery to allow for backup ventricular pacing as necessary (Strong Recommendation, Low Quality Evidence).

**Values and preferences (2010)**
This recommendation reflects the relative ease of placement of epicardial temporary pacing wires at the time of surgery as well as the potential for significant morbidity associated with postoperative bradycardia.

**Recommendation 7 - Post-op AF with rapid response: beta-blocker, CCB, or amiodarone (2010)**
We recommend that postoperative AF with a rapid ventricular response be treated with a beta-blocker, a non-dihydropyridine calcium antagonist, or amiodarone to establish ventricular rate control. In the absence of a specific contraindication, the order of choice is as listed (Strong Recommendation, High Quality Evidence).

**Values and preferences (2010)**
This recommendation places a high value on the randomized controlled trials investigating rate control as an alternative to rhythm control for AF, recognizing that these trials did not specifically address the postoperative period.

**Recommendation 8 - Rate-control or rhythm-control strategy for post-op AF (2016, updated from 2010)**
We recommend that postoperative AF may be appropriately treated with either a ventricular response rate-control strategy or a rhythm-control strategy (Strong Recommendation, Moderate Quality Evidence).

**Values and preferences (2016, updated from 2010)**
This recommendation places a high value on the randomized controlled trials investigating rate control as an alternative to rhythm control for AF, including one trial specifically addressing the cardiac postoperative period. Choice of strategy should therefore be individualized based on the degree of symptoms experienced by the patient.
**Recommendation 9 - Reconsideration of ongoing therapy 6-12 weeks post-op (2010)**

We recommend that, when anticoagulation therapy, rate-control therapy, and/or rhythm control therapy has been prescribed for postoperative AF, formal reconsideration of the ongoing need for such therapy should be undertaken 6-12 weeks later (Strong Recommendation, Moderate Quality Evidence).

**Values and preferences (2010)**

This recommendation reflects the high probability that postoperative AF will be a self-limiting process that does not require long-term therapy.
Part 11 – Peri-procedural Anticoagulation Management

Recommendation 1 - Decision considerations (2014)
We recommend that in a patient with AF or atrial flutter, a decision to interrupt antithrombotic therapy for an invasive procedure must balance the risks of a thromboembolic event (as indicated by a higher CHADS2 score, mechanical heart valve, or rheumatic heart disease) with those of a bleeding event (as indicated by a higher HASBLED score and procedures with higher bleeding risks) (Strong Recommendation, Low Quality Evidence).

Recommendation 2 – OAC interruption not necessary for most lower risk procedures (2016, updated from 2014)
We suggest that interruption of anticoagulant therapy, particularly for vitamin K antagonists, in a patient with AF/AFL is not necessary for most procedures with a low risk of bleeding, such as cardiac device implantation (pacemaker or implantable defibrillator), and most dental procedures (Table 1) (Conditional Recommendation, Moderate Quality Evidence).

Recommendation 3 – OAC interruption of anticoagulant therapy for medium to high risk procedures (2014)
We recommend that interruption of anticoagulant therapy in a patient with AF or AFL will be necessary for most procedures with an intermediate or high risk of major bleeding (see Table 1) (Strong Recommendation, Low Quality Evidence).

Values and preferences (2014)
Practitioners responsible for preventing thromboembolic events in patients with AF/AFL and practitioners responsible for preventing peri-procedural bleeding each tend to over-value their unique roles. Recommendations 1-3 are intended to promote a balanced approach to minimizing the combined outcome of peri-procedural thromboembolic events and major bleeding.

Table S10 (Table 1 from 2016): Bleeding risks for various invasive/surgical procedures

<table>
<thead>
<tr>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any surgery or procedure with neuraxial (spinal or epidural) anesthesia</td>
</tr>
<tr>
<td>Neurosurgery (intracranial or spinal)</td>
</tr>
<tr>
<td>Cardiac surgery (e.g. CABG, heart valve replacement)</td>
</tr>
<tr>
<td>Major intra-abdominal surgery</td>
</tr>
<tr>
<td>Major vascular surgery (e.g. aortic aneurysm repair, aortofemoral bypass)</td>
</tr>
<tr>
<td>Major orthopedic surgery (e.g. hip or knee replacement)</td>
</tr>
<tr>
<td>Lung resection surgery</td>
</tr>
<tr>
<td>Urological surgery (e.g. prostatectomy, bladder tumour resection)</td>
</tr>
<tr>
<td>Extensive cancer surgery (e.g. pancreas, liver)</td>
</tr>
<tr>
<td>Intestinal anastomosis surgery</td>
</tr>
<tr>
<td>Reconstructive plastic surgery</td>
</tr>
<tr>
<td>Selected procedures (e.g. kidney biopsy, prostate biopsy, cervical cone biopsy,</td>
</tr>
<tr>
<td>pericardiocentesis, colonic polypectomy)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intermediate risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other intra-abdominal surgery (e.g. laparoscopic cholecystectomy, hernia repair)</td>
</tr>
<tr>
<td>Category</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Other general surgery (e.g. breast)</td>
</tr>
<tr>
<td>Other intrathoracic surgery</td>
</tr>
<tr>
<td>Other orthopedic surgery</td>
</tr>
<tr>
<td>Other vascular surgery</td>
</tr>
<tr>
<td>Non-cataract ophthalmologic surgery</td>
</tr>
<tr>
<td>Gastroscopy or colonoscopy with biopsies</td>
</tr>
<tr>
<td>Selected procedures (e.g. bone marrow biopsy, lymph node biopsy)</td>
</tr>
<tr>
<td>Complex dental procedure (e.g. multiple tooth extractions)</td>
</tr>
<tr>
<td><strong>Low risk</strong></td>
</tr>
<tr>
<td>Dental extractions (1 or 2 teeth), endodontic (root canal) procedure,</td>
</tr>
<tr>
<td>subgingival scaling or other cleaning</td>
</tr>
<tr>
<td>Cataract surgery</td>
</tr>
<tr>
<td>Dermatologic procedures (e.g. biopsy)</td>
</tr>
<tr>
<td>Gastroscopy or colonoscopy without biopsies</td>
</tr>
<tr>
<td>Coronary angiography</td>
</tr>
<tr>
<td>Permanent pacemaker insertion or internal defibrillator placement (if bridging anticoagulation is not used)</td>
</tr>
<tr>
<td>Selected procedures (e.g. thoracentesis, paracentesis, arthrocentesis)</td>
</tr>
</tbody>
</table>

The procedural/surgical risk categorization list may be updated based on new information, and can be found at Thrombosis Canada (http://thrombosiscanada.ca)

**Recommendation 4 - Aspirin or clopidogrel interruption 5-7 days prior to procedure (2016, updated from 2014)**
When a decision to interrupt aspirin or clopidogrel (or other ADP receptor/P2Y12 inhibitors including prasugrel, ticagrelor), therapy for an invasive procedure has been made for a patient with AF/AFL, we suggest that interruption begin 5-7 days before the procedure, except for procedures with a very high risk of bleeding, in which case we suggest interruption 7-10 days before the procedure (Conditional Recommendation, Low Quality Evidence).

**Recommendation 5 - Warfarin interruption 5 days prior to procedure (2014)**
When a decision to interrupt warfarin therapy for an invasive procedure has been made for a patient with AF or AFL, we suggest that the interruption begin 5 days prior to the procedure and that a procedure with a low bleeding risk may proceed when the INR is <1.5 and a procedure with an intermediate or high bleeding risk may proceed when the INR is <1.2 (Conditional Recommendation, Low Quality Evidence).

**Recommendation 6 - Stop apixaban or rivaroxaban 1-2 days pre-low risk; 2-3 days pre-medium or high-risk procedure (2014)**
When a decision to interrupt apixaban or rivaroxaban therapy for an invasive procedure has been made for a patient with AF or AFL, we suggest that the interruption begin 1-2 days prior to the day of a procedure with a low risk of major bleeding and 2-3 days prior to the day of a procedure with an intermediate or high risk of major bleeding (Conditional Recommendation, Low Quality Evidence).
Recommendation 7 - Stop dabigatran 1-2 days prior pre-low risk; 2-3 days pre-medium or high-risk procedure, depending on renal function (2014)
When a decision to interrupt dabigatran therapy for an invasive procedure has been made for a patient with AF or AFL, we suggest that the interruption begin 1-2 days before a procedure with low risk of major bleeding and 2-3 days before a procedure with an intermediate or high risk of major bleeding for CrCl is ≥80mL/min (Conditional Recommendation, Low Quality Evidence). The upper end of these ranges should be used if CrCl is 50-80 mL/min, an additional day should be added for CrCl 30-50 mL/min, and in case CrCl is found to be <30 mL/min, yet one more day of dabigatran withdrawal should be added (Conditional Recommendation, Low Quality Evidence).

Recommendation 8 - Bridging therapy in a patient at high risk of thromboembolic events (2016, updated from 2014)
When a decision to interrupt warfarin-therapy for an invasive procedure has been made for a patient with AF/AFL, we suggest that bridging therapy with LMWH or UFH be instituted when the INR is below therapeutic level only in patients at high risk of thromboembolic events (CHADS2 ≥4, mechanical heart valve, stroke/TIA within 3 months, rheumatic heart disease) (Conditional Recommendation, Low Quality Evidence).

Recommendation 9 - No bridging for patients on NOAC for procedures requiring interruption of anticoagulation (2016)
We recommend no bridging (LMWH or UFH) for NVAF patients on NOAC undergoing elective surgery or invasive procedures requiring interruption of anticoagulation (Strong recommendation, Moderate Evidence).

Practical tip (2016)
Duration of pre-procedural interruption of NOACs should be adjusted according to renal function (see supplementary appendix, part 11, recommendations 6-7). The Thrombosis Canada Perioperative Anticoagulant Management Algorithm is a helpful tool to aid decisions regarding peri-procedural anticoagulation. [http://thrombosiscanada.ca/?page_id=502&calc=perioperativeAnticoagulantAlgorithm](http://thrombosiscanada.ca/?page_id=502&calc=perioperativeAnticoagulantAlgorithm)

Recommendation 10 - Heparin bridging pre-procedure (2016, updated from 2014)
We recommend that when LMWH or UFH bridging is used for an invasive procedure such therapy be started prior to the procedure when the INR is below the therapeutic level and be stopped 24 hours prior to the procedure for LMWH and 4-6 hours prior to the procedure for UFH (Strong recommendation, Low Quality Evidence).

Recommendation 11 – Heparin bridging post-procedure (2016, updated from 2014)
When LMWH or UFH bridging is used for an invasive procedure, we suggest that such therapy be restarted after the procedure when hemostasis is established (usually 24 hours for a procedure with a low risk of bleeding and 48-72 hours for a procedure with an intermediate or high risk of bleeding) in prophylactic dosages for the first 24 to 72 hours and then increased to therapeutic dosages. Bridging is then continued until INR is in the therapeutic range (Conditional Recommendation, Low Quality Evidence).

Recommendation 12 – Warfarin, ASA, clopidogrel restarted when hemostasis is established (2014)
When warfarin, ASA, or clopidogrel therapy has been interrupted for an invasive procedure we suggest that such therapy be restarted after the procedure when hemostasis is established (usually 24-48 hours
for a procedure with a low risk of bleeding and 48-72 hours for a procedure with an intermediate or high risk of bleeding) (Conditional Recommendation, Low Quality Evidence).

**Recommendation 13 – NOAC restarted one day after hemostasis is established (2014)**
When apixaban, dabigatran, or rivaroxaban therapy has been withdrawn for an invasive procedure we suggest that such therapy be restarted after the procedure one day after hemostasis is established (usually 48 hours for a procedure with a low risk of bleeding and 72 hours for a procedure with an intermediate or high risk of bleeding) (Conditional Recommendation, Low Quality Evidence).

**Values and preferences (2016, updated from 2014)**
All of these peri-procedural recommendations assume that the practitioner has weighed an individual patient’s risks of thromboembolic events and of experiencing a major bleeding event in the peri-procedural period as discussed in the previous section and has elected to interrupt antithrombotic therapy. These recommendations are then intended to summarize how the goal of interrupted therapy can be achieved, with high value placed on achieving that goal just before the procedure is performed. Recommendations regarding heparin bridging place a higher value on prevention of stroke and systemic thromboembolism in patients at high risk than on the inconvenience and higher risk of major bleeding associated with heparin bridging. Recommendations regarding the timing of post-procedural reintroduction of antithrombotic therapy are intended to promote a balanced approach to minimizing the combined outcome of post-procedural thromboembolic events and major bleeding.
Canadian Cardiovascular Society Atrial Fibrillation Primary Panel

Dr. Laurent Macle (co-chair) – Montreal Heart Institute, Université de Montréal, Montreal, Quebec
Dr. Atul Verma (co-chair) – Southlake Regional Health Centre, Newmarket, Ontario
Dr. Jason Andrade – University of British Columbia, Vancouver, British Columbia and Montreal Heart Institute, Université de Montréal, Montreal, Quebec
Dr. Clare Atzema – Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario
Dr. Alan D. Bell – University of Toronto, Toronto, Ontario
Dr. John A. Cairns – University of British Columbia, Vancouver, British Columbia
Dr. Stuart Connolly – McMaster University and Hamilton General Hospital, Hamilton, Ontario
Dr. Jafna L. Cox – QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia
Dr. Paul Dorian – St. Michael’s Hospital, University of Toronto, Toronto, Ontario
Dr. David J. Gladstone – Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario
Dr. Jeff S. Healey – McMaster University and Hamilton General Hospital, Hamilton, Ontario,
Ms. Kori Leblanc – University Health Network, University of Toronto, Toronto, Ontario
Dr. L. Brent Mitchell – Libin Cardiovascular Institute of Alberta, University of Calgary, and Alberta Health Services, Calgary, Alberta
Dr. Stanley Nattel – Montreal Heart Institute, Université de Montréal, Montreal, Quebec
Dr. Ratika Parkash – QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia
Dr. Louise Pilote – McGill University Health Centre, Montréal, Québec
Dr. Mike Sharma – McMaster University and Hamilton General Hospital, Hamilton, Ontario and The Canadian Stroke Network, Ottawa, Ontario
Dr. Allan Skanes – London Heart Institute, Western University, London, Ontario
Dr. Mario Talajic – Montreal Heart Institute, Université de Montréal, Montreal, Quebec
Dr. Teresa S.M Tsang – University of British Columbia, Vancouver, British Columbia
Dr. Subodh Verma – St. Michael’s Hospital, University of Toronto, Toronto, Ontario
Canadian Cardiovascular Society Atrial Fibrillation Secondary Panel

Dr. David Bewick – Horizon Health Network, St. John, New Brunswick
Dr. Vidal Essebag – McGill University Health Centre and Hôpital Sacré-Cœur de Montréal, Montréal, Québec
Dr. Peter G. Guerra – Montreal Heart Institute, Université de Montréal, Montreal, Quebec
Dr. Milan Gupta – McMaster University and St. Michael’s Hospital, University of Toronto, Toronto, Ontario
Dr. Brett Heilbron – St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia
Dr. Charles R. Kerr – St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia
Dr. Paul Khairy – Montreal Heart Institute, Université de Montréal and Montreal Health Innovations Coordinating Centre, Montreal, Quebec
Dr. Bob Kiaii – London Heart Institute, Western University, London, Ontario
Dr. George J. Klein – Schulich School of Medicine & Dentistry, Western University, London, Ontario
Dr. Simon Kouz – Centre Intégré de Sante et Service Sociaux de Lanaudière and Université Laval, Québec, Québec
Dr. Daniel Ngui – Vancouver, British Columbia
Dr. Pierre Pagé – Montreal Heart Institute, Université de Montréal and Hôpital Sacré-Cœur de Montréal, Montreal, Quebec
Dr. P. Timothy Pollak – University of Calgary, Calgary, Alberta
Dr. Calum J. Redpath – University of Ottawa Heart Institute, Ottawa, Ontario
Dr. Jan Surkes – Langley Memorial Hospital, Langley, British Columbia
Dr. Richard P. Whitlock – McMaster University, Hamilton, Ontario
Dr. D. George Wyse – Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta
Framework for Application of GRADE and Evidence Tables

There is a growing expectation that guideline developers document their approach to systematic reviews of evidence and development of recommendations. Now it is preferred that guideline writing panels apply GRADE with more rigour and document the "evidence review to recommendation" process. The goal is to have writing panels follow a systematic approach to the development of recommendations based on evidence and produce documentation that provides transparency of process to readers and stakeholders.

This supplement explains the new application of GRADE and the steps the AF guideline writing groups followed throughout the guideline development process:

1. Develop your health care questions in PICO format.
2. Conduct an evidence search and document the search strategy; databases, timeframe, inclusion, exclusion criteria, etc.
3. Review the studies to assess high level risk of bias and rate the evidence and document in table format.
4. Map the "evidence review to recommendation" process and document in an evidence table (see pages that follow).
5. Develop recommendations based on review of evidence and GRADE the recommendations in CCS format:

   • ALL recommendations will begin with we recommend (where strength and quality of evidence are strong) and we suggest (where strength and quality of evidence is not strong).
   • For strength of recommendations, we will use strong and conditional/weak as qualifiers.
   • For quality of evidence, we will use the words very low, low, moderate, or high.

For more information on the framework for application of GRADE, please visit ccs.ca.
Evidence Table: Management of antithrombotic therapy in patients with concomitant AF and CAD

<table>
<thead>
<tr>
<th>PICO Question (Population/Patients, Intervention, Comparator, Outcome)</th>
<th>Literature Search Strategy (Database, timeframe [yr], inclusion/exclusion terms, language restrictions, etc.)</th>
<th>Study Quality Assessment (Use separate tool – appropriate for each study type)</th>
<th>Overall Quality (Very Low; Low; Moderate; High)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI patients, OAC + clopidogrel vs TT; and A + C vs TT; Outcomes Major bleeding and composite of Death, MI, Stroke and stent thrombosis</td>
<td>Medline (OVID), accepted search strategy of D'Ascenzo et al through to June 14, 2014. The D'Ascenzo produced for OAC vs TT: 9 studies showing Major bleeds, reduced to 3 if restricted to RCT (1 only and very small) and 2 adjusted analyses and 5 studies showing composite outcome, reduced to none if restricted to RCT and adjusted analyses. The D'Ascenzo produced for OAC+C vs TT: 5 studies showing major bleeds (all were RCT) (1) or adjusted analyses and 6 studies showing composite outcome, reduced to 4 if restricted to RCT and adjusted analyses. Then ran the search again for 2013 onward and found 1 additional Chinese meta-analysis, several additional small studies (all retrospective) and only 2 important studies (Hess and Fiedler).</td>
<td>Meta-analysis</td>
<td>High</td>
</tr>
</tbody>
</table>

| PCI patients, OAC + clopidogrel vs TT; Primary outcome TIMI bleeding, secondary and composite of Death, MI, Stroke and stent thrombosis | WOJEST. DeWilde WJ et al. Lancet 2013;3;10:13-28. | RCT Primary outcome was TIMI bleeding at 1 year, significantly reduced, as was BARC 3 bleeding but TIMI major bleeding not significantly reduced. Study not powered for secondary outcome of ischemic events but this was significantly reduced. Relatively small study, only 69% of subjects had AF, 75% were elective PCI, standard procedures to reduce bleeding under-utilized. | Moderate to high |

| Patients receiving OAC + ASA who had PCI-DES. Addition of clopidogrel for 6 wk vs 6 mo. Primary outcome was composite (death, ST, stroke, TIMI major bleed) at 9 mo. | ISAR Triple. Fiedler KA. JACC 2015;65:1619-29. | RCT, open label Primary outcome in 9.8% of 6 wk vs 8.8% in 6 mo (p=0.63). TIMI major bleed 5.3% vs 4% (P=0.44). Relatively small ss. | High |

| AF patients ≥65, with AMI and stenting. TT vs DAPT. Primary effectiveness outcome 2yr MACCE (death, readm for MI or stroke. Primary safety outcome readm for bleeding. | Hess CN. JACC 2015;66:616-27. | Registry-based study ACTION Registry, US national database, 4959 patients discharged home on DAPT. Of these 27.6% on TT, 72.4% DAPT only. Unadjusted and adjusted comparisons (patient, treatment and hospital characteristics) | Moderate |

| Patients with PCI-DES (48% stable/silent angina, 45% NSTEMI, ≤ 10% STEMI). DAPT (ASA + either clopid, prasugrel or ticagrelor) for short term (<12 mo) vs 12 mo (and longer term >12 mo) vs 12 mo. Primary outcomes, CV mortality, MI, ST, major bleed, overall mortality. Secondary repeat revascularization, CVA, comb’n of cardiac and CVA. | Navarese EP. BMJ 2015;350:h1618 | Meta-analysis of RCTs This is a PCI study. No info about AF | High |

<table>
<thead>
<tr>
<th>Other Considerations</th>
<th>Imprecision</th>
<th>Inconsistencies</th>
<th>Indirectness</th>
<th>Limitations</th>
<th>Other Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inconsistencies</td>
<td>69% had AF, 75% had elective PCI. Wide CIs for TIMI major bleed (NS), for BARC3 bleed (P=0.011) and for composite outcome (NS).</td>
<td>The findings are driven primarily by non-ACS patients. For the comparison of A+C vs TT, the CIs are relatively wide and the I² is 60%. When analysis confined to RCTs and adjusted analysis, CIs more narrow and I² &lt;5. For Cx + OAC vs TT, all trials are RCT (only 1) or adjusted analyses and I² =16%. This is the most recent and best meta-analysis available.</td>
<td>The important questions are TT for how long, and the efficacy/safety of alternatives (DAPT and OAC+C). Duration of TT assessed. Wide CI for primary composite outcome with HR 1.14 for 6 wk vs 6 mo, also wide CI for major bleed. All patients on TT at beginning, tests only duration of TT.</td>
<td>High (but observational)</td>
<td></td>
</tr>
</tbody>
</table>

| Indirectness | Reasonably precise for adjusted outcomes of MACCE, death, MI and centered around HR of 1.0. For ischemic stroke HR 0.66 for TT, but still NS. Major bleed clearly more with TT [after adjustment HR 1.61, P=0.0001] and intracranial bleed (adj HR 2.04, P=0.01) | Large study |

| Imprecision | Wide CI for primary composite outcome with HR 1.14 for 6 wk vs 6 mo, also wide CI for major bleed. All patients on TT at beginning, tests only duration of TT. | High |

| Other Considerations | Moderate | High |

| Overall Quality | High |

**Population:** Patients with AF and CAD. **Intervention:** Antithrombotic therapy (OAC, DAPT, or no therapy). **Comparator:** Control group (no therapy, or alternative therapy). **Outcome:** Primary outcomes: death, MI, Stroke, composite endpoints. Secondary outcomes: bleeding, stent thrombosis, drug-related complications. **Study Design:** RCTs.
### Evidence Table: Management of antithrombotic therapy in patients with concomitant AF and CAD

<table>
<thead>
<tr>
<th>PICO Question</th>
<th>Literature Search Strategy</th>
<th>Study Quality Assessment</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with PCI-DES. Most received first generation DES. DAPT (ASA + either clopid [most], prasugrel or ticagrelor) for short term vs longer term. These durations varied from trial to trial all the way from 3 mo vs 12, to 6 mo vs 12, 6 vs 24, to 12 vs 30, 12 vs 36. Primary outcome was all-cause mortality. Secondaries included cardiac death, non-card death, MI, stroke, ST, major bleed, any bleed.</td>
<td></td>
<td>Meta-analysis of RCTs</td>
<td>Palmerini T. Lancet 2015;385:2371-82.</td>
</tr>
<tr>
<td>Patients undergoing PCI (most with ACS). Cobalt chromium everolimus eluting stent vs BMS. Primary outcome cardiac mortality at longest available follow-up &gt;1 yr. Secondary were all-cause death, MI, ST, TVR, composite of card death or NV, composite of all-cause death or MI.</td>
<td></td>
<td>Individual patient meta-analysis of RCTs</td>
<td>Valmigli M. Bmj 2014;349:g6427 doi.</td>
</tr>
</tbody>
</table>

<p>|</p>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Limitations</th>
<th>Inconsistencies</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other Considerations</th>
<th>Overall Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmerini T. Lancet 2015;385:2371-82.</td>
<td>Meta-analysis of RCTs</td>
<td>This is a PCI study. No info about AF</td>
<td></td>
<td></td>
<td></td>
<td>Shorter vs longer gives HR 0.82, P=0.02 for all death, 0.93, p=0.52 for card mortality and 0.67, p=0.006 for non-card mortality. Shorter had lower risk of major bleed, but higher risk of MI and ST.</td>
<td>high</td>
</tr>
<tr>
<td>Valmigli M. Bmj 2014;349:g6427 doi.</td>
<td>Individual patient meta-analysis of RCTs</td>
<td>This is a PCI study. No info about AF</td>
<td></td>
<td></td>
<td></td>
<td>Everolimus cardiac mortality HR 0.67, P=0.02, MI 0.71, P=0.01, ST 0.48, P=0.001, TVR 0.29, P=0.001. All cause death HR 0.83, P=0.14. No change with duration of DAPT, ACS vs stable CAD</td>
<td>high</td>
</tr>
<tr>
<td>Ruff CT. Lancet 2013</td>
<td>Meta-analysis of RCTs</td>
<td></td>
<td>I² =48% for MI. I² = 0% for all-cause mortality.</td>
<td></td>
<td></td>
<td>These were studies of AF patients, but about 11-18% had prior MI. The RRs were ischemic stroke 0.92, P=0.10, hemorrhagic stroke 0.49, P=0.0001, MI 0.97, P=0.37, all-cause mortality 0.90, P=0.003, ih hemorrhage 0.48, P=0.0001, GI bleed 1.25, P=0.043</td>
<td>high</td>
</tr>
</tbody>
</table>
## Evidence Table: Real-life data with NOACs/ Reversal agents for NOACs

<table>
<thead>
<tr>
<th>PICO Question (Population/Patients, Intervention, Comparator, Outcome)</th>
<th>Literature Search Strategy (Databases, timeframe [yrs], inclusion/exclusion terms, language restrictions, etc.)</th>
<th>Study Quality Assessment Quality Assessment (Use separate tool – appropriate for each study type)</th>
<th>Overall Quality (Very Low; Low; Moderate; High)</th>
</tr>
</thead>
<tbody>
<tr>
<td>see bias and quality checklist</td>
<td>see bias and quality checklist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ross B, Miller MA, Ditch K, Tran M</td>
<td>Case Series</td>
<td>Serious limitations; observational data only</td>
<td>N/A</td>
</tr>
<tr>
<td>Aronis KN, Hylek EM</td>
<td>Review article</td>
<td>Article inclusion strategy not included in paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Kumar R, Smith RE, Henry BL</td>
<td>Retrospective Case series</td>
<td>Serious limitations; observational data only; small numbers</td>
<td>N/A</td>
</tr>
<tr>
<td>Dibu JR, Weimer JM, Ahrens C, Manno E, Frontera JA</td>
<td>Prospective Case Series</td>
<td>Important limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Dzik WH</td>
<td>Review article</td>
<td>Important limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Barco S, Cheung, YW, Coppens M Et al</td>
<td>DB, PC, crossover study in healthy volunteers</td>
<td>Some limitations</td>
<td>Inconsistencies</td>
</tr>
<tr>
<td>Grandhi R, Newman WC, Zhang X, et al</td>
<td>Retrospective Case Series</td>
<td>Important limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Faust AC, Woodard S, Koehl JL et al</td>
<td>Case reports</td>
<td>Serious limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Masotti L, Lorernzini G, Servalle C et al</td>
<td>Consecutive case series; multicenter</td>
<td>Serious limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Pahs L, Beavers C, Schuler P</td>
<td>Retrospective case review; multicenter</td>
<td>Serious limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Sholzberg M, Pavenksi K, Shehata N</td>
<td>Retrospective case review; multicenter</td>
<td>Serious limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>Pollack CV, Reilly PA, Eikelboom J et al</td>
<td>Prospective Cohort Study</td>
<td>Important limitations</td>
<td>N/A</td>
</tr>
<tr>
<td>PICO Question (Population/Patients, Intervention, Comparator, Outcome)</td>
<td>Literature Search Strategy (Databases, timeframe [yrs], inclusion/exclusion terms, language restrictions, etc.)</td>
<td>Study Quality Assessment Quality Assessment (Use separate tool – appropriate for each study type)</td>
<td>Overall Quality (Very Low; Low; Moderate; High)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Siegal DM, Curnutte JT, Connolly SJ et al</td>
<td>R, DB, PC study in health older volunteers</td>
<td>Some limitations</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### Evidence Table: Peri-procedural anticoagulation management

<table>
<thead>
<tr>
<th>PICO Question</th>
<th>Literature Search Strategy</th>
<th>Study Quality Assessment</th>
<th>Overall Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>For AF patients on OAC undergoing elective surgical or invasive procedures, should current recommendations for OCA interruptions, with/without bridging, be revised?</td>
<td>PubMed/Medline: Jan 2014 - Jan 2016. Limits: Human, English. Search terms: atrial fibrillation, anticoagulation, bridging anticoagulation, perioperative bridging, peri-ablation bridging</td>
<td>Reference: Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373:823-833</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td>As above</td>
<td>Reference: Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anti-coagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131:488-494</td>
<td>Large, prospective, observational Registry (USA)</td>
</tr>
<tr>
<td>PICO Question</td>
<td>Literature Search Strategy</td>
<td>Study Quality Assessment</td>
<td>Overall Quality</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------</td>
<td>--------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Should digoxin be used for rate control in AF</td>
<td>Farshi et al</td>
<td>Clinical Trial</td>
<td>No serious inconsistencies</td>
</tr>
<tr>
<td></td>
<td>David et al</td>
<td>Nonrandomized clinical study</td>
<td>No serious inconsistencies</td>
</tr>
<tr>
<td></td>
<td>Turakhia et al</td>
<td>Analysis of RCT data</td>
<td>No serious inconsistencies</td>
</tr>
<tr>
<td></td>
<td>Vamos et al</td>
<td>Systemic review and meta-analysis</td>
<td>No serious inconsistencies</td>
</tr>
<tr>
<td></td>
<td>Washam et al</td>
<td>Retrospective analysis of RCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrade et al</td>
<td>Retrospective analysis of combined data from 2 RCTs</td>
<td></td>
</tr>
<tr>
<td>PICO Question (Population/Patients, Intervention, Comparator, Outcome)</td>
<td>Literature Search Strategy (Databases, timeframe [yrs], inclusion/exclusion terms, language restrictions, etc.)</td>
<td>Study Quality Assessment</td>
<td>Quality Assessment (Use separate tool -- appropriate for each study type)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Does atrial pacing reduce pre-discharge POAF as compared to placebo in patients undergoing cardiac surgery</td>
<td>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2011), MEDLINE (from 1946 to July 2011), EMBASE (from 1974 to July 2011) and CINAHL (from 1981 to July 2011)</td>
<td>Arsenault Cochrane 2013</td>
<td>3+</td>
</tr>
<tr>
<td>Does magnesium reduce POAF (same PCO)</td>
<td>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2011), MEDLINE (from 1946 to July 2011), EMBASE (from 1974 to July 2011) and CINAHL (from 1981 to July 2011)</td>
<td>Arsenault Cochrane 2013</td>
<td>3+</td>
</tr>
<tr>
<td>Do steroids reduce POAF (same PCO)</td>
<td>Embase, Medline, Cochrane, CINAHL, and OVID</td>
<td>Whitlock EHJ 2008</td>
<td>3+</td>
</tr>
<tr>
<td>Do PUFA reduce POAF (same PCO)?</td>
<td>PUBMED, EMBASE, Cochrane Library, and Google Scholar databases</td>
<td>Zhang Journal of Cardiology 2013</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials</td>
<td>Costanzo J Thorac Cardiovasc Surg 2013</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mosaffarian JAMA 2012</td>
<td>4+</td>
</tr>
<tr>
<td>Does Colchicine reduce POAF (same PCO)</td>
<td>Cochrane Collaboration Database of Randomized Trials, ClinicalTrials.gov, CINAHL, Google Scholar, PubMed, and Scopus</td>
<td>Imazio JAMA 2014</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Verma et al. BMC Cardiovascular Disorders 2015</td>
<td>3+</td>
</tr>
<tr>
<td>Does statin therapy reduce post-operative AF (same PCO)</td>
<td>PubMed Cochrane since last guidelines (2010), post-operative AF, statins, HMG-CoA reductase inhibitor, English</td>
<td>Zheng, NEJM 2016</td>
<td>4+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11), Ovid MEDLINE (1950 to November 2013Week 3) and Ovid EMBASE (1980 to 3 December 2013 (Week 48)</td>
<td>Kuhn Cochrane 2015</td>
<td>4+</td>
</tr>
</tbody>
</table>